{"chunk_id": "tnm_lung_chunk_0", "text": "Lung: Protocol for Cancer Staging Documentation\nChapter Summary\nACS.AJCC.Protocol.Lung.2024.v09.00.00\nRequired Use Date: January 1, 2025\nCancers Staged Using This Staging System\nThis classification applies to carcinomas of the lung, including non-small cell and small cell carcinomas, and\nbronchopulmonary carcinoid (neuroendocrine) tumors.\nCancers Not Staged Using This Staging System\nThese histopathologic types of\ncancer...\nAre staged according to the classification for...\nSarcomas of the lung\nSoft Tissue Sarcoma of the Abdomen and Thoracic Visceral\nOrgans\nOther rare tumors of the lung\nNo AJCC staging system\nIntroductory Comments:\nThe following protocol is intended to standardize communication of critical components of cancer staging. It\nincludes corresponding explanatory notes that provide the level of evidence for each critical element. While the\nfocus of this protocol with synoptic report format is on cancer staging for clinical care and registry support,\ninformation on additional and emerging prognostic factors is included. Additional information on staging may be\nfound in the AJCC 8  Edition Chapter 1: Principles of Cancer Staging.\nStaging Report Format\nInstructions\nInstructions for the use of this staging report:\nThis staging report was designed to demonstrate documentation of critical elements for AJCC stage\nclassifications of primary carcinomas (including non-small cell carcinomas, small cell carcinomas and\nbronchopulmonary carcinoid (neuroendocrine) tumors) of the lung.\nExplanatory notes are provided for further descriptions and specifications for each data field.\n\u2022 AJCC data elements required for staging are identified with an asterisk (*).\n\u2022 Additional data elements that are clinically significant but not required for staging are identified with a dagger\nsymbol (\u2020).\n\u2022 Emerging prognostic data elements are optional and include factors for which there is not sufficiently strong\ndata to warrant routine collection. Such factors may be abstracted for some institutional and national\ndatabases. As the evidence base grows, these factors will be reevaluated on a periodic basis.\nSummary of Changes\nth", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841186", "page": 1, "cancer_type": "Lung", "category": "Unknown", "section": null, "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 2137}}
{"chunk_id": "tnm_lung_chunk_1", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n1/60\n\nChange\nDetails of Change\nLevel of\nEvidence", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841473", "page": 1, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 210}}
{"chunk_id": "tnm_lung_chunk_2", "text": "Definition of Primary Tumor\n\n(T)\nInvasion of adjacent lobe has been added as a T2a category\ncriteria\nIII", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841484", "page": 2, "cancer_type": "Lung", "category": "Unknown", "section": "Definition of Primary Tumor", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 104}}
{"chunk_id": "tnm_lung_chunk_3", "text": "Definition of Primary Tumor\n\n(T)\nAzygos vein, thoracic nerve roots (i.e., T1, T2) and stellate\nganglion added as a T3 category criteria\nIII", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841488", "page": 2, "cancer_type": "Lung", "category": "Unknown", "section": "Definition of Primary Tumor", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 139}}
{"chunk_id": "tnm_lung_chunk_4", "text": "Definition of Primary Tumor\n\n(T)\nThymus, vagus nerve, supra-aortic arteries, brachiocephalic veins,\nsubclavian vessels, vertebral body, lamina, spinal canal, cervical\nnerve roots, brachial plexus (i.e., trunks, divisions, cords or\nterminal nerves) are specified as T4 category criteria\nIII\nDefinition of Regional\nLymph Nodes (N)\nN2 subdivided into N2a (involvement of a single N2 nodal station)\nand N2b (involvement of multiple N2 nodal stations)\nII\nDefinition of Distant\nMetastasis (M)\nM1c subdivided into M1c1 (multiple extrathoracic metastases in a\nsingle organ system) and M1c2 (multiple extrathoracic metastases\nin multiple organ systems)\nII\nAJCC Prognostic Stage\nGroups\nT1 N1 M0 changed from stage IIB to stage IIA\nII\nAJCC Prognostic Stage\nGroups\nT1 N2a M0 assigned to stage IIB\nII\nAJCC Prognostic Stage\nGroups\nT2 N2b M0 assigned to stage IIIB\nII\nAJCC Prognostic Stage\nGroups\nT3 N2a M0 assigned to stage IIIA\nII\nNote AF: Additional Factors\nImpacting Treatment\nDecisions During First\nTreatment Phase\nSpread through air spaces (STAS) introduced as an additional\nhistologic descriptor together with the already existing vascular\ninvasion (V), lymphatic permeation (L) and perineural invasion\n(Pn)\nI\nDiagnostic Phase\nIdentification of Primary Site (Note S)\nNOTE: This list includes topography codes and terms from the International Classification of Diseases for\nOncology (ICD-O).\nCode\nDescription\n___ C34.0 Main bronchus\n___ C34.1 Upper lobe, lung\n___ C34.2 Middle lobe, lung\n___ C34.3 Lower lobe, lung\n___ C34.8 Overlapping lesion of lung\n___ C34.9 Lung, not otherwise specified (NOS)", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841492", "page": 2, "cancer_type": "Lung", "category": "Unknown", "section": "Definition of Primary Tumor", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 1588}}
{"chunk_id": "tnm_lung_chunk_5", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n2/60\n\nHistopathologic Type (Note HT)\nAdditional data elements that are clinically significant but not required for staging are identified with a dagger\nsymbol (\u2020).\n\u2020Histopathologic Codes NOTE: This list includes histology codes and preferred terms from the WHO\nClassification of Tumours and the International Classification of Diseases for Oncology (ICD-O). Most of the\nterms in this list represent malignant behavior. For cancer reporting purposes, behavior codes /3 (denoting\nmalignant neoplasms), /2 (denoting in situ neoplasms), and in some cases /1 (denoting neoplasms with uncertain\nand unknown behavior) may be appended to the 4-digit histology codes to create a complete morphology code.\nCode\nDescription\n___ 8010\nNon-small cell carcinoma, NOS\n___ 8012\nLarge cell carcinoma\n___ 8013\nLarge cell neuroendocrine carcinoma\n___ 8013\nCombined large cell neuroendocrine carcinoma\n___ 8022\nPleomorphic carcinoma\n___ 8023\nNUT carcinoma\n___ 8031\nGiant cell carcinoma\n___ 8032\nSpindle cell carcinoma\n___ 8041\nSmall cell carcinoma\n___ 8044\nThoracic SMARCA4- deficient undifferentiated tumor\n___ 8045\nCombined small cell carcinoma\n___ 8070\nSquamous cell carcinoma\n___ 8070\nSquamous cell carcinoma in situ\n___ 8071\nKeratinizing squamous cell carcinoma\n___ 8072\nNon-keratinizing squamous cell carcinoma\n___ 8082\nLymphoepithelial-like carcinoma\n___ 8083\nBasaloid squamous cell carcinoma\n___ 8140\nAdenocarcinoma\n___ 8144\nEnteric adenocarcinoma\n___ 8200\nAdenoid cystic carcinoma\n___ 8230\nSolid adenocarcinoma\n___ 8240\nCarcinoid tumor, NOS/neuroendocrine tumor, NOS\n___ 8240\nTypical carcinoid/neuroendocrine tumor, grade 1\n___ 8249\nAtypical carcinoid/neuroendocrine tumor, grade 2\n___ 8250\nAdenocarcinoma in situ, non-mucinous\n___ 8250\nLepidic adenocarcinoma\n___ 8253\nInvasive mucinous adenocarcinoma\n___ 8253\nAdenocarcinoma in situ, mucinous\n___ 8254\nMixed invasive mucinous and non-mucinous adenocarcinoma", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841495", "page": 2, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 2058}}
{"chunk_id": "tnm_lung_chunk_6", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n3/60\n\n___ 8256\nMinimally invasive adenocarcinoma, non-mucinous\n___ 8257\nMinimally invasive adenocarcinoma, mucinous\n___ 8260\nPapillary adenocarcinoma\n___ 8265\nMicropapillary adenocarcinoma\n___ 8310\nHyalinizing clear cell carcinoma\n___ 8333\nFetal adenocarcinoma\n___ 8430\nMucoepidermoid carcinoma\n___ 8480\nColloid adenocarcinoma\n___ 8551\nAcinar adenocarcinoma\n___ 8560\nAdenosquamous carcinoma\n___ 8562\nEpithelial-myoepithelial carcinoma\n___ 8972\nPulmonary blastoma\n___ 8980\nCarcinosarcoma\n___ 8982\nMyoepithelial carcinoma\n___ 8000\nNeoplasm, malignant\n___ 8010\nCarcinoma, NOS\nHistology is not ideal for clinical use in patient care, as it describes an unspecified or outdated\ndiagnosis. Data collectors may use this code only if there is not enough information in the medical record\nto document a more specific diagnosis.\nSources: WHO Classification of Tumours Editorial Board. Lung. Lyon (France): International Agency for", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841498", "page": 3, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 1082}}
{"chunk_id": "tnm_lung_chunk_7", "text": "International Agency for Research on Cancer, World Health Organization. International Classification of\n\nDiseases for Oncology. ICD-O-3.2 Online.  Used with permission.\n\u2020Grade (G) (Note G)\nAdditional data elements that are clinically significant but not required for staging are identified with a dagger\nsymbol (\u2020).\n\u2020Grade is assigned based on histopathologic assessment.\nG\nG Definition\n___ GX Grade cannot be assessed\n___ G1 Well differentiated\n___ G2 Moderately differentiated\n___ G3 Poorly differentiated\n___ G4 Undifferentiated\nModalities Used for Diagnosis and Staging\nClinical Examination (Note CE)\n\u00a7\n\u00a7\n\u00a7\nth\n2\n3", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841501", "page": 4, "cancer_type": "Lung", "category": "Unknown", "section": "International Agency for Research on Cancer, World Health Organization. International Classification of", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 617}}
{"chunk_id": "tnm_lung_chunk_8", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n4/60\n\n____ Cognitive, central nervous, or cranial nerve abnormalities\n____ Peripheral muscle weakness or sensory deficits\n____ Jugular venous distension\n____ Dysphonia (hoarseness)\n____ Lymphadenopathy\n____ Stridor or wheezing\n____ Diminished breath sounds\n____ Abdominal organomegaly\n____ Cutaneous lesion, soft tissue mass, or bony tenderness\n____ Other\nImaging (Note I)\n____ Posteroanterior and lateral chest x-rays\n____ Contrast-enhanced CT of the chest and upper abdomen\n____ Positron emission tomography/computed tomography (PET/CT)\n____ Contrast-enhanced MRI or CT of the brain\n____ Bone scan\n____ Other\nDiagnostic Procedures/Surgical Procedures\n____ Thoracentesis\n____ Pericardiocentesis\n____ Scalene lymph node and supraclavicular lymph node biopsies\n____ Bronchoscopy with biopsy, brushing, washing, transbronchial needle aspiration\n____ Endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA)\n____ Endoscopic ultrasound fine-needle aspiration (EUS-FNA)\n____ Combined EBUS-TBNA/EUS-FNA\n____ Mediastinoscopy and parasternal mediastinotomy\n____ Extended cervical mediastinoscopy\n____ Video-assisted mediastinoscopic lymphadenectomy (VAMLA)\n____ Transcervical extended mediastinoscopic lymphadenectomy (TEMLA)\n____ Video-assisted thoracoscopic surgery (VATS)\n____ Robotic-assisted thoracoscopic surgery (RATS)\n____ Pleuroscopy", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841504", "page": 4, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 1509}}
{"chunk_id": "tnm_lung_chunk_9", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n5/60\n\n____ Image-guided transthoracic biopsy\n____ Pleurodesis\n____ Wedge resection\n____ Segmentectomy\n____ Lobectomy\n____ Bilobectomy\n____ Pneumonectomy\n____ Carinal resection\n____ Bronchial and vascular sleeve resections\n____ Extended lung resection to chest wall, diaphragm, pericardium, etc.\n____ Other\nOther\n____Cytology (sputum, pleural fluid, pericardial fluid)\nStaging Phase (Classification)\nClinical Staging and Workup\nThis table is a simplified algorithm of the investigations and procedures utilized to generate lung cancer clinical\nTNM staging information.\nIts purpose is to provide clarity regarding appropriate modalities to use in determining the individual categories of\nthe lung cancer clinical TNM staging.\nDisclaimer: The table represents common approaches to staging and work up for this cancer. Some or all of\nthese tests are used in staging the cancer and are provided as a reference. The table is not a guideline for\ntreatment and should not be used in this manner but instead utilized to identify how each of these tests\ncontribute to the determination of T, N, M categories and Stage.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841507", "page": 5, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 1270}}
{"chunk_id": "tnm_lung_chunk_10", "text": "DIAGNOSTIC WORKUP\n\nDESCRIPTION\nSPECIFIC", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841509", "page": 6, "cancer_type": "Lung", "category": "Unknown", "section": "DIAGNOSTIC WORKUP", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 39}}
{"chunk_id": "tnm_lung_chunk_11", "text": "TNM CATEGORY\n\nClinical Exam\nPhysical examination\nAssess neck, axillary, and inguinal\nlymph nodes; hepatomegaly,\nsplenomegaly; neurologic\nabnormalities\nN3, M1b-c\nPulmonary function tests\nAssess lung volume and capacity\nNone\nBronchoscopy\nSize, location, spread\nT0-T4\nMediastinoscopy, extended cervical\nmediastinoscopy, parasternal\nmediastinotomy\nDirect invasion of mediastinum, nodal\ninvolvement", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841512", "page": 6, "cancer_type": "Lung", "category": "TNM-staging", "section": "TNM CATEGORY", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 393}}
{"chunk_id": "tnm_lung_chunk_12", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n6/60\n\nPleuroscopy, video-assisted\nthoracoscopic surgery (VATS), robotic-\nassisted thoracoscopic surgery (RATS)\nPleural involvement, nodal involvement T3-T4, N1-N3, M1a\nImaging\nCT chest and upper abdomen\nChest and upper abdomen\nT0-T4, N1-N3, M1a-c\nPET/CT\nSkull to mid-thigh\nT0-T4, N1-N3, M1a-c\nMRI head\nHead\nM1b-c\nMRI chest and abdomen\nChest and abdomen\nT0-T4, N1-N3, M1a-c\nCT abdomen and pelvis\nAbdomen and pelvis\nM1a-c\nLaboratory Studies\nSputum cytology\nTumor not visualized\nTX\nPleural or pericardial fluid cytology\nIntrathoracic metastasis\nM1a\nPathological Staging and Workup\nThis table is a simplified algorithm of the investigations and procedures utilized to generate lung cancer\npathological TNM staging information.\nIts purpose is to provide clarity regarding appropriate modalities for the pathologist and managing physician to\nuse in determining the individual categories of the lung cancer pathological TNM staging.\nDisclaimer: The table represents common approaches to staging and work up for this cancer. Some or all of\nthese tests are used in staging the cancer and are provided as a reference. The table is not a guideline for\ntreatment and should not be used in this manner but instead utilized to identify how each of these tests\ncontribute to the determination of T, N, M categories and Stage.\nCATEGORY\nSPECIMEN\nPATHOLOGIST", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841515", "page": 6, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 1502}}
{"chunk_id": "tnm_lung_chunk_13", "text": "MANAGING PHYSICIAN\n\n(Stage Documented by\nCancer Registry)\nGeneral\nInformation\n\u2022 Assignment of pTNM categories\nare based on surgical\nresection specimen, as well\nas intraoperative findings,\nbiopsy procedures and clinical\nevaluation up to the point of\ndefinitive surgical treatment, if\navailable\n\u2022 All other surgical procedure\nspecimens use cTNM; for\nexample, biopsy of a positive\nregional lymph node without\nsurgical resection of the\n\u2022 Assignment of pTNM\ncategories for the patient\nrequires use of information\nfrom all biopsy procedures\nperformed during the\nclinical evaluation up to\nand including definitive\nsurgical treatment\n\u2022 Requires information from\nclinical assessment or\nimaging studies or\nintraoperative findings to\nassign pTNM categories", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841518", "page": 7, "cancer_type": "Lung", "category": "Unknown", "section": "MANAGING PHYSICIAN", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 745}}
{"chunk_id": "tnm_lung_chunk_14", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n7/60\n\nprimary carcinoma is classified\nas cN1\n(may not change pTNM,\nbut must be considered)\npTX\nNot for use by pathologist;\nassigned only by managing\nphysician\nMay assign if unable to\ndetermine pT category after\nsurgical resection\npTX\nNot for use by pathologist;\nassigned only by managing\nphysician\nSpecial definition for lung -\nmalignant cells in sputum or\nbronchial washings but not\nseen on imaging or\nbronchoscopy\npT0\nNo tumor found in specimen and\nnever identified on diagnostic\nbiopsies\nNo tumor found in specimen\nand never identified on\ndiagnostic biopsies\npTis [AIS,\nSCIS]\nWedge, segmental,\nlobectomy, bilobectomy,\nsleeve resection, or\npneumonectomy\nsurgical resection\nInvasive size of tumor\nPathology reports +/-\nappropriate clinical exam,\nimaging studies, and\nintraoperative findings\npT1\npT1mi\npT1a\npT1b\npT1c\npT2\nSize or these features: main\nbronchus involvement, invades\nvisceral pleura, or\natelectasis/obstructive pneumonitis\npT2a\npT2b\npT3\nSize, invading specific structures\npT4\nSize or invading specific structures\npNX\nNot for use by pathologist;\nassigned only by managing\nphysician\n\u2022 May assign if unable to\ndetermine pN category\n\u2022 No regional node(s)\nsampled or resected\npN0\nFine Needle\nAspiration (FNA), core\nneedle biopsy, lymph\nnode dissection\n(including procedures\nperformed prior to\ndefinitive surgical\nresection)\nRequires:\n\u2022 At least one lymph node\nsampled\n\u2022 May require information from a\nprevious node biopsy\nprocedure to assign pN\ncategory\nRequires:\n\u2022 Same information as the\npathologist\n\u2022 Supplement with clinically\npositive nodes from\nexamination or imaging\npN1\npN2\npN2a", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841520", "page": 7, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 1756}}
{"chunk_id": "tnm_lung_chunk_15", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n8/60\n\nNote: These procedures\nin the absence of a\nsurgical resection are\ncN\n\u2022 For FNA or core biopsy: use (f)\nmodifier\nPrimary site surgical resection is\nrequired to assign pN\npN2b\npN3\ncM0\nNot assigned by pathologist\nWhen no clinical or pathologic\nevidence of metastatic disease,\nassign cM0\ncM1\nNot assigned by pathologist\nSigns/symptoms of distant\nmetastasis, and/or imaging\nfindings, assign cM1\ncM1a\nNot assigned by pathologist\nSigns/symptoms of separate\ntumor nodule in contralateral\nlobe, pleural or pericardial\nnodules, or malignant pleural or\npericardial effusion\ncM1b\nNot assigned by pathologist\nSigns/symptoms of single\nextrathoracic distant metastasis\ncM1c\nNot assigned by pathologist\nSigns/symptoms of multiple\nextrathoracic distant\nmetastases\ncM1c1\nNot assigned by pathologist\nSigns/symptoms of multiple\nextrathoracic distant\nmetastases in a single organ\nsystem\ncM1c2\nNot assigned by pathologist\nSigns/symptoms of multiple\nextrathoracic distant\nmetastases in multiple organ\nsystems\npM1\nPathologic confirmation\nof metastatic disease by\nany method\n\u2022 Do not use pMX or pM0\n\u2022 Pathologic confirmation\nincludes procedures performed\nprior to definitive resection\n\u2022 Do not use pMX or pM0\n\u2022 pM1 includes all clinically\nconfirmed metastasis if at\nleast one metastatic site is\nconfirmed microscopically\npM1a\nSampling of tissues or\nfluid cytology\n\u2022 Microscopic confirmation of\nseparate tumor nodules in\ncontralateral lobe, pleural\nnodules, pericardial nodules,\nor malignant pleural or\npericardial effusion\nRequires pathological\nassessment of at least one\nmetastatic site\n\u2022 Separate tumor nodules in\ncontralateral lobe, pleural\nnodules, pericardial", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841523", "page": 8, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 1807}}
{"chunk_id": "tnm_lung_chunk_16", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n9/60\n\nnodules, or malignant\npleural or pericardial\neffusion\n\u2022 pM1 includes all clinically\nconfirmed metastasis if at\nleast one metastatic site is\nconfirmed microscopically\npM1b\nSampling of tissues\n\u2022 Microscopic confirmation of\nsingle extrathoracic distant\nmetastasis\nRequires pathological\nassessment of the single\nmetastatic site\n\u2022 Single extrathoracic distant\nmetastasis\n\u2022 pM1 includes the clinically\nconfirmed metastasis if it is\nconfirmed microscopically\npM1c\nSampling of tissues\n\u2022 Microscopic confirmation of\nmultiple extrathoracic distant\nmetastases\nRequires pathological\nassessment of at least one\nmetastatic site\n\u2022 Multiple extrathoracic\ndistant metastasis\n\u2022 pM1 includes all clinically\nconfirmed metastasis if at\nleast one metastatic site is\nconfirmed microscopically\npM1c1\nSampling of tissues\n\u2022 Microscopic confirmation of\nmultiple extrathoracic distant\nmetastases in a single organ\nsystem\nRequires pathological\nassessment of at least one\nmetastatic site\n\u2022 Multiple extrathoracic\ndistant metastases in a\nsingle organ system\n\u2022 pM1 includes all clinically\nconfirmed metastases if at\nleast one metastatic site is\nconfirmed microscopically\npM1c2\nSampling of tissues\n\u2022 Microscopic confirmation of\nmultiple extrathoracic distant\nRequires pathological\nassessment of at least one\nmetastatic site", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841526", "page": 9, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 1458}}
{"chunk_id": "tnm_lung_chunk_17", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n10/60", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841528", "page": 10, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 169}}
{"chunk_id": "tnm_lung_chunk_18", "text": "11/8/25, 11:55 AM\n\nmetastases in multiple organ\nsystems\n\u2022 Multiple extrathoracic\ndistant metastases in\nmultiple organ systems\n\u2022 pM1 includes all clinically\nconfirmed metastases if at\nleast one metastatic site is\nconfirmed microscopically\nStaging Rules for Lung\nCommon staging scenarios:\n1) Lung cancer treated surgically\nThe scenario is a tumor identified on imaging. Diagnostic workup begins with physical exam and imaging, and\nmay include bronchoscopy with biopsy, nodal aspiration (EBUS-TBNA), mediastinoscopy. Other diagnostic\nprocedures, such as percutaneous needle or core biopsy of extra-thoracic organs may be necessary. Based on\nthis information the physician assigns the clinical staging (A in figure above) of cT for the primary lesion, cN for\nany nodal involvement, and cM for distant metastasis found on physical exam, imaging or biopsy, and pM for\nmicroscopic proof of distant metastasis. The treatment plan based on the clinical stage is a surgical resection.\nThe extent of the resection depends on the primary tumor. The pathologist assigns pT, pN, and pM (when lymph\nnodes and any distant metastases are sampled) based on the resection specimen. The managing physician then\nassigns the pathological staging (B in figure above) pT and pN based on the clinical stage information, the\noperative findings, and the resected specimen pathology report information, and the cM category based on\nphysical exam, imaging, and unsampled operative findings or the pM category based on physical exam, imaging,\noperative findings, and pathology report which provides microscopic evidence on at least one of these metastatic\nsites.\n2) Lung cancer treated with systemic therapy and/or radiotherapy with potential subsequent surgical\nresection\nIn more extensive disease, after clinical staging it may be determined the tumor is unresectable. Clinical\nstaging (A in figure above), cT, cN, and cM/pM are assigned based on physical examination, imaging findings,\nand any biopsies as described in scenario 1. The patient is treated with appropriate therapy. Assessment after\ntherapy may be assigned posttherapy clinical staging (C in figure above) using ycT for the primary tumor, ycN\nfor the regional nodes, and the M category assigned at the time of the initial clinical staging, either cM/pM.\nA clinical complete response (cCR) of the primary tumor would be assigned ycT0. A cCR of the lymph nodes\nwould be assigned ycN0.\nIf this evaluation shows residual tumor which is resectable, the patient may undergo surgical resection. The\npathologist will assign ypT based on assessment of the primary tumor and ypN for regional nodes. The\nmanaging physician will then use the yc stage combined with the operative findings and the pathology report to\nassign the posttherapy pathological staging (D in figure above) ypT, ypN, and the M category assigned at the\ntime of the initial clinical staging, either cM/pM.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841531", "page": 10, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 2903}}
{"chunk_id": "tnm_lung_chunk_19", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n11/60\n\nA pathological complete response (pCR) of the primary tumor would be assigned ypT0. A pCR of the lymph\nnodes would be assigned ypN0.\nRules for Classification\nClassifications specify the timeframe in the patient's care and the criteria used to assign TNM. The same\nclassification should be used throughout the assignment of TNM and stage group.\nClinical Classification (c) (Note C)\nPathological Classification (p) (Note P)\nPosttherapy Clinical Classification (yc) (Note YC)\nPosttherapy Pathological Classification (yp) (Note YP)\nAdditional classifications for recurrence/retreatment and autopsy:\nRecurrence/Retreatment TNM Classification (r) (Note R)\nAutopsy TNM Classification (a) (Note A)\nAssignment of AJCC TNM\nAJCC data elements required for staging are identified with an asterisk (*).\n*Stage classification based on time frame and criteria (see Supplemental Information)\n____ c (clinical)\n____ p (pathological)\n____ yc (posttherapy clinical)\n____ yp (posttherapy pathological)\n*Definition of Primary Tumor (T) (Note T)\nT\nCategory\nT Criteria", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841534", "page": 11, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 1214}}
{"chunk_id": "tnm_lung_chunk_20", "text": "___ TX\n\nPrimary tumor cannot be assessed.\nIncludes tumors proven by the presence of malignant cells in sputum or bronchial washings\nbut not visualized by imaging or bronchoscopy", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841536", "page": 12, "cancer_type": "Lung", "category": "Unknown", "section": "___ TX", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 177}}
{"chunk_id": "tnm_lung_chunk_21", "text": "___ T0\n\nNo evidence of primary tumor\n___ Tis\nCarcinoma in situ\nSquamous cell carcinoma in situ (SCIS)\nAdenocarcinoma in situ (AIS): adenocarcinoma with pure lepidic pattern, \u2264 3 cm in greatest\ndimension", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841539", "page": 12, "cancer_type": "Lung", "category": "Unknown", "section": "___ T0", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 202}}
{"chunk_id": "tnm_lung_chunk_22", "text": "___ T1\n\nTumor \u2264 3 cm in greatest dimension surrounded by lung or visceral pleura, or in a lobar or\nmore peripheral bronchus.\n___\nT1mi\nMinimally invasive adenocarcinoma: adenocarcinoma (\u2264 3 cm in greatest dimension) with a\npredominantly lepidic pattern and \u2264 5 mm invasion in greatest dimension", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841541", "page": 12, "cancer_type": "Lung", "category": "Unknown", "section": "___ T1", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 293}}
{"chunk_id": "tnm_lung_chunk_23", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n12/60\n\n___\nT1a\nTumor \u2264 1 cm in greatest dimension\nOR\nTumor of any size whose invasive component is limited to the bronchial wall and may extend\nproximal to the main bronchus, this is an uncommon superficial, spreading tumor\n___\nT1b\nTumor > 1 cm but \u2264 2 cm in greatest dimension\n___\nT1c\nTumor > 2 cm but \u2264 3 cm in greatest dimension", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841544", "page": 12, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 493}}
{"chunk_id": "tnm_lung_chunk_24", "text": "___ T2\n\nTumor > 3 cm but \u2264 5 cm in greatest dimension\nOR\nTumor \u2264 4 cm with one or more of the following features:\n\u2022 Invades visceral pleura\n\u2022 Invades an adjacent lobe\n\u2022 Involves main bronchus (up to but not including the carina)\nor\nassociated with atelectasis or obstructive pneumonitis, extending to the hilar regions,\ninvolving either part of or the entire lung\n___\nT2a\nTumor > 3 cm but \u2264 4 cm in greatest dimension\nOR\nTumor \u2264 4 cm in greatest dimension with one or more of the following features:\n\u2022 Invades visceral pleura\n\u2022 Invades an adjacent lobe\n\u2022 Involves main bronchus (up to but not including the carina)\nor\nassociated with atelectasis or obstructive pneumonitis, extending to the hilar regions,\ninvolving either part of or the entire lung\n___\nT2b\nTumor > 4 cm but \u2264 5 cm in greatest dimension with or without any of the following features:\n\u2022 Invades visceral pleura\n\u2022 Invades an adjacent lobe\n\u2022 Involves main bronchus (up to but not including the carina)\nor", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841546", "page": 13, "cancer_type": "Lung", "category": "Unknown", "section": "___ T2", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 968}}
{"chunk_id": "tnm_lung_chunk_25", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n13/60\n\nassociated with atelectasis or obstructive pneumonitis, extending to the hilar regions,\ninvolving either part of or the entire lung", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841549", "page": 13, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 300}}
{"chunk_id": "tnm_lung_chunk_26", "text": "___ T3\n\nTumor > 5 cm but \u2264 7 cm in greatest dimension\nOR\nTumor \u2264 7 cm with one or more of the following features:\n\u2022 Invades parietal pleura or chest wall\n\u2022 Invades pericardium, phrenic nerve or azygos vein\nAlthough these structures lie within the mediastinum, the degree of mediastinal\npenetration by the tumor needed to invade these structures is not counted as T4\n\u2022 Invades thoracic nerve roots (i.e., T1, T2) or stellate ganglion\n\u2022 Separate tumor nodule(s) in the same lobe as the primary", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841552", "page": 14, "cancer_type": "Lung", "category": "Unknown", "section": "___ T3", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 491}}
{"chunk_id": "tnm_lung_chunk_27", "text": "___ T4\n\nTumor > 7 cm in greatest dimension\nOR\nTumor of any size with one or more of the following features:\n\u2022 Invades mediastinum (except structures listed in T3), thymus, trachea, carina, recurrent\nlaryngeal nerve, vagus nerve, esophagus or diaphragm\n\u2022 Invades heart, great vessels (aorta, superior/inferior vena cava, intrapericardial\npulmonary arteries/veins), supra-aortic arteries or brachiocephalic veins\n\u2022 Invades subclavian vessels, vertebral body, lamina, spinal canal, cervical nerve roots or\nbrachial plexus (i.e., trunks, divisions, cords or terminal nerves)\n\u2022 Separate tumor nodule(s) in a different ipsilateral lobe than that of the primary", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841554", "page": 14, "cancer_type": "Lung", "category": "Unknown", "section": "___ T4", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 654}}
{"chunk_id": "tnm_lung_chunk_28", "text": "Primary Tumor Suffix\n\n___ (m) Multiple synchronous primary tumors\n*Definition of Regional Lymph Nodes (N) (Note N)\nN\nCategory\nN Criteria", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841557", "page": 14, "cancer_type": "Lung", "category": "Unknown", "section": "Primary Tumor Suffix", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 136}}
{"chunk_id": "tnm_lung_chunk_29", "text": "___ NX\n\nRegional lymph nodes cannot be assessed", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841560", "page": 14, "cancer_type": "Lung", "category": "Unknown", "section": "___ NX", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 47}}
{"chunk_id": "tnm_lung_chunk_30", "text": "___ N0\n\nNo tumor involvement of regional lymph node(s)", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841562", "page": 14, "cancer_type": "Lung", "category": "Unknown", "section": "___ N0", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 54}}
{"chunk_id": "tnm_lung_chunk_31", "text": "___ N1\n\nTumor involvement of ipsilateral peribronchial and/or ipsilateral hilar and/or ipsilateral\nintrapulmonary lymph node station(s), including involvement by direct extension", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841564", "page": 14, "cancer_type": "Lung", "category": "Unknown", "section": "___ N1", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 178}}
{"chunk_id": "tnm_lung_chunk_32", "text": "___ N2\n\nTumor involvement of ipsilateral mediastinal nodal station(s) and/or subcarinal lymph node\nstation", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841567", "page": 14, "cancer_type": "Lung", "category": "Unknown", "section": "___ N2", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 106}}
{"chunk_id": "tnm_lung_chunk_33", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n14/60\n\n___\nN2a\nTumor involvement of a single ipsilateral mediastinal nodal station or of the subcarinal nodal\nstation\n___\nN2b\nTumor involvement of multiple ipsilateral mediastinal nodal stations with or without\ninvolvement of the subcarinal nodal station", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841570", "page": 14, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 416}}
{"chunk_id": "tnm_lung_chunk_34", "text": "___ N3\n\nTumor involvement of contralateral mediastinal, contralateral hilar, ipsilateral/contralateral\nscalene, or ipsilateral/contralateral supraclavicular lymph node station(s)\nRegional Lymph Nodes Suffix\n___ (f) FNA or core needle biopsy\n*Definition of Distant Metastasis (M) (Note M)\nM\nCategory\nM Criteria\n___ cM0\nNo distant metastasis\n___ cM1\nDistant metastasis\n___\ncM1a\nMetastasis in pleural or pericardial nodules, and/or malignant pleural or pericardial effusions,\nand/or separate tumor nodule(s) in a contralateral lobe\nNote: Most pleural (pericardial) effusions with lung cancer are a result of the tumor. In a few\npatients, however, multiple microscopic examinations of pleural (pericardial) fluid are\nnegative for tumor, and the fluid is non-bloody and not an exudate. If these elements and\nclinical judgment dictate that the effusion is not related to the tumor, the effusion should be\nexcluded as a staging descriptor.\n___\ncM1b\nSingle extrathoracic metastasis in a single organ system (including involvement of a single\nnon-regional node)\n___\ncM1c\nMultiple extrathoracic metastases in a single or multiple organ system(s)\n___\ncM1c1\nMultiple extrathoracic metastases in a single organ system\nFor example, the skeleton is considered one organ. Several metastases in a single bone or\nseveral metastases in several bones are classified as M1c1.\n___\ncM1c2\nMultiple extrathoracic metastases in multiple organ systems\n___ pM1\nMicroscopic confirmation of distant metastasis\n___\npM1a\nMicroscopic confirmation of metastasis in pleural or pericardial nodules, and/or malignant\npleural or pericardial effusions, and/or separate tumor nodule(s) in a contralateral lobe\nNote: Most pleural (pericardial) effusions with lung cancer are a result of the tumor. In a few\npatients, however, multiple microscopic examinations of pleural (pericardial) fluid are\nnegative for tumor, and the fluid is non-bloody and not an exudate. If these elements and\nclinical judgment dictate that the effusion is not related to the tumor, the effusion should be\nexcluded as a staging descriptor.\n___\npM1b\nMicroscopic confirmation of single extrathoracic metastasis in a single organ system\n(including involvement of a single non-regional node)", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841572", "page": 15, "cancer_type": "Lung", "category": "Unknown", "section": "___ N3", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 2221}}
{"chunk_id": "tnm_lung_chunk_35", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n15/60\n\n___\npM1c\nMicroscopic confirmation of multiple extrathoracic metastases in a single or multiple organ\nsystem(s)\n___\npM1c1\nMicroscopic confirmation of multiple extrathoracic metastases in a single organ system\nFor example, the skeleton is considered one organ. Several metastases in a single bone or\nseveral metastases in several bones are classified as M1c1.\n___\npM1c2\nMicroscopic confirmation of multiple extrathoracic metastases in multiple organ systems\nPrognostic Factors Required for Stage Grouping (Note PFR)\nBeyond the factors used to assign T, N, or M categories, no additional prognostic factors are required for stage\ngrouping.\nAJCC Prognostic Stage Groups (Note PSG)\nAJCC data elements required for staging are identified with an asterisk (*).\n*AJCC prognostic stage group is assigned based on the stage classification and categories chosen.\nWhen T is... And N is... And M is...\nThen the stage group is...", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841575", "page": 15, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 1084}}
{"chunk_id": "tnm_lung_chunk_36", "text": "___ TX\n\nN0\nM0\nOccult carcinoma\n___ Tis\nN0\nM0\n0\n___ T1mi-T1a\nN0\nM0\nIA1\n___ T1b\nN0\nM0\nIA2\n___ T1c\nN0\nM0\nIA3\n___ T2a\nN0\nM0\nIB\n___ T2b\nN0\nM0\nIIA", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841577", "page": 16, "cancer_type": "Lung", "category": "Unknown", "section": "___ TX", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 140}}
{"chunk_id": "tnm_lung_chunk_37", "text": "___ T1\n\nN1\nM0\nIIA", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841579", "page": 16, "cancer_type": "Lung", "category": "Unknown", "section": "___ T1", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 17}}
{"chunk_id": "tnm_lung_chunk_38", "text": "___ T3\n\nN0\nM0\nIIB", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841582", "page": 16, "cancer_type": "Lung", "category": "Unknown", "section": "___ T3", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 17}}
{"chunk_id": "tnm_lung_chunk_39", "text": "___ T1\n\nN2a\nM0\nIIB\n___ T2a-T2b\nN1\nM0\nIIB", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841584", "page": 16, "cancer_type": "Lung", "category": "Unknown", "section": "___ T1", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 40}}
{"chunk_id": "tnm_lung_chunk_40", "text": "___ T4\n\nN0\nM0\nIIIA", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841587", "page": 16, "cancer_type": "Lung", "category": "Unknown", "section": "___ T4", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 18}}
{"chunk_id": "tnm_lung_chunk_41", "text": "___ T3-T4\n\nN1\nM0\nIIIA", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841589", "page": 16, "cancer_type": "Lung", "category": "Unknown", "section": "___ T3-T4", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 21}}
{"chunk_id": "tnm_lung_chunk_42", "text": "___ T1\n\nN2b\nM0\nIIIA", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841592", "page": 16, "cancer_type": "Lung", "category": "Unknown", "section": "___ T1", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 19}}
{"chunk_id": "tnm_lung_chunk_43", "text": "___ T2-T3\n\nN2a\nM0\nIIIA", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841595", "page": 16, "cancer_type": "Lung", "category": "Unknown", "section": "___ T2-T3", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 22}}
{"chunk_id": "tnm_lung_chunk_44", "text": "___ T2-T3\n\nN2b\nM0\nIIIB", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841597", "page": 16, "cancer_type": "Lung", "category": "Unknown", "section": "___ T2-T3", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 22}}
{"chunk_id": "tnm_lung_chunk_45", "text": "___ T4\n\nN2a-N2b\nM0\nIIIB", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841600", "page": 16, "cancer_type": "Lung", "category": "Unknown", "section": "___ T4", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 23}}
{"chunk_id": "tnm_lung_chunk_46", "text": "___ T1-T2\n\nN3\nM0\nIIIB", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841602", "page": 16, "cancer_type": "Lung", "category": "Unknown", "section": "___ T1-T2", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 21}}
{"chunk_id": "tnm_lung_chunk_47", "text": "___ T3-T4\n\nN3\nM0\nIIIC\n___ Any T\nAny N\nM1a-M1b\nIVA\n___ Any T\nAny N\nM1c1-M1c2 IVB\nAdditional Factors Impacting Treatment Decisions During First Treatment\nPhase (Note AF)", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841605", "page": 16, "cancer_type": "Lung", "category": "Unknown", "section": "___ T3-T4", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 167}}
{"chunk_id": "tnm_lung_chunk_48", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n16/60\n\nIntroduction\nAdditional data elements that are clinically significant but not required for staging are identified with a dagger\nsymbol (\u2020).", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841607", "page": 16, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 308}}
{"chunk_id": "tnm_lung_chunk_49", "text": "Prognostic Tumor Characteristics\n\n1. \u2020Radiographic features\n2. \u2020Pathologic features (including STAS)\n3. \u2020Genetic or molecular features\nNon-Tumor Factors\n1. \u2020Patient demographics\n2. \u2020Mode of presentation\n3. \u2020Functional status\n4. \u2020Comorbid conditions posing a competing risk of death\n5. \u2020Quality of care\nData Collection\nRegistry Data Collection Guidance\n1. \u2020Grade pathological\n2. \u2020Vascular invasion\n3. \u2020Lymphatic permeation\n4. \u2020Perineural invasion\n5. \u2020Spread through air spaces (STAS)\n6. \u2020Residual tumor (R status)\n7. \u2020EGFR mutation\n8. \u2020BRAF mutation\n9. \u2020KRAS mutation\n10. \u2020METex14 skipping mutation\n11. \u2020ERBB2/HER2 mutation\n12. \u2020NTRK1/2/3 mutation\n13. \u2020RET mutation\n14. \u2020ALK gene rearrangement\n15. \u2020ROS 1 gene rearrangement", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841610", "page": 17, "cancer_type": "Lung", "category": "Unknown", "section": "Prognostic Tumor Characteristics", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 722}}
{"chunk_id": "tnm_lung_chunk_50", "text": "16. \u2020PD-L1\n\nEmerging Factors for Data Collection\n1. \u2020Tobacco use", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841613", "page": 17, "cancer_type": "Lung", "category": "Unknown", "section": "16. \u2020PD-L1", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 64}}
{"chunk_id": "tnm_lung_chunk_51", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n17/60", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841616", "page": 17, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 169}}
{"chunk_id": "tnm_lung_chunk_52", "text": "11/8/25, 11:55 AM\n\n2. \u2020Functional status\n3. \u2020Nodule density\nExplanatory Notes\nIntroduction\nLung cancer is the most frequent cancer diagnosed and the leading cause of cancer mortality in the world. In\n2020, approximately 2.2 million new cases of lung cancer were estimated to be diagnosed, and 1.8 million\ndeaths occurred globally (18.0% of the total cancer deaths).  Lung cancer is classified according to the TNM\nsystem, which codes the anatomic extent of the disease and is the most important prognosticator we have to\ndate. As such, the classification does not include clinical, biological, molecular, or genetic descriptors, although\nthey may be used in combination with the TNM classification to build prognostic groups, different from stage\ngroups, which are combinations of tumors with TNMs of similar prognosis.\nOver the past two decades, the revision of the TNM classification for lung cancer has derived from analyses of\nthe new retrospective and prospective databases collected through the International Association for the Study of\nLung Cancer (IASLC) Staging Project, which is an international effort to study and improve the current staging\nsystem for thoracic cancers. Following the publication of the 8th edition of the TNM classification as the product\nof the second phase of the international Staging Project, the IASLC launched the third phase of its Staging\nProject in 2017. For this latest phase, a new database of lung cancer cases diagnosed between January 2011\nand December 2019 has been established.\nThe newly established database is composed of 124,581 cases, of which 101,033 (81.1%) were submitted as\nbatch datasets and 23,548 (18.9%) were submitted via electronic data capture (EDC). The data came from 25\ncountries and 75 unique sites. After excluding cases with incomplete data, 87,043 cases were eligible for\nanalysis. Of these eligible cases, there were 52,069 (59.8%) invasive adenocarcinomas, 15,872 (18.2%)\nsquamous cell carcinomas, 1,142 (1.3%) adenocarcinomas in situ, 1,100 (1.3%) adenosquamous carcinomas,\n1,057 (1.2%) large cell carcinomas, 5,530 (6.4%) small cell lung carcinomas, and 689 (0.8%) large cell\nneuroendocrine carcinomas. Approximately 67% of the cases underwent surgical treatment, with or without\nchemotherapy or radiotherapy. Multifaceted analyses of the database were performed, and results have been\npublished as the basis for the recommendations for changes in Version 9 of the TNM classification.\nNote S: Identification of Primary Tumor\nFor the purpose of TNM classification, the lungs are not paired organs but a single organ.\nBasically, they are\nformed by the bronchi and the lung parenchyma. Lung cancer is a bronchogenic neoplasm arising from the\nepithelial cells of the bronchial mucosa or from the cells lining the alveoli. The right lung has three lobes \u2014\nupper, middle, and lower \u2014 with three, two, and five segments, respectively. The left lung has two lobes \u2014 upper\nand lower \u2014 with five and four segments, respectively. (Figure Lung-Anatomy) The segment is considered the\nsmallest anatomic unit of the lung.\nAlthough all lung cancers may be located in any part of the lung, squamous cell and small cell carcinomas tend\nto arise from the mucosa of the more central bronchi, involving the lobar origins and the main bronchi. This\ncentral location often causes bronchial obstruction and atelectasis, either lobar or complete. The natural\nprogression of these central tumors is to invade the bronchial wall and the mediastinal structures, such as the\npericardium, the phrenic nerve, the superior vena cava, and more rarely, the esophagus, the aorta, and the\nheart. On the other hand, adenocarcinomas tend to locate in the periphery of the lung, with extension to the\nvisceral pleura, often causing pleural dissemination and malignant pleural effusion, and to the chest wall. The\nearlier adenocarcinomas, such as adenocarcinoma in situ and minimally invasive adenocarcinoma, also tend to\nbe located peripherally. The fact that lung lesions do not generate pain, and that lung compliance allows tumors\nto grow within the lung parenchyma accounts for the late diagnosis of the disease. Only when the tumor causes\nbronchial obstruction and subsequent atelectasis, pneumonia or dyspnea, bleeding from the bronchial mucosa,\n4\n5\n6-9\n10", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841618", "page": 17, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 4298}}
{"chunk_id": "tnm_lung_chunk_53", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n18/60", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841621", "page": 18, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 169}}
{"chunk_id": "tnm_lung_chunk_54", "text": "11/8/25, 11:55 AM\n\nor pain due to invasion of the parietal pleura, do patients present with symptoms, and the diagnostic process\nbegins. A high index of suspicion is needed to avoid minimizing the nonspecific symptoms and attributing them to\nbenign diseases.\nFigure Lung-Anatomy. Anatomy illustration for the lung and its lobes.\nNote HT: Histopathologic Type\nThis classification applies to carcinomas of the lung, including non-small cell and small cell carcinomas, and\nbronchopulmonary carcinoid (neuroendocrine) tumors.\nNote G: Grade (G)\nFor resected non-mucinous lung adenocarcinomas, the IASLC grading system is recommended.\nGrade Histologic Patterns\n1\nLepidic predominant with no or < 20% high grade patterns\n2\nAcinar or papillary predominant with no or < 20% high grade patterns\n3\nAny tumor with \u2265 20% high grade patterns (solid, micropapillary, cribriform or complex glandular\npatterns)\nNote CE: Clinical Examination\nA thorough physical exam can prime a clinician's expectations of and alertness to radiographic findings that\nfacilitate staging or direct the clinician to perform an invasive diagnostic procedure that could obviate the need for\nunnecessary radiographic testing. If related to lung cancer, the following physical exam findings portend\nadvanced stage disease. In the absence of a lung cancer related etiology, efforts should be made to identify an\netiology for the physical exam finding as the diagnosis may impact treatment decisions linked to functional status\nand comorbid conditions.\nCognitive, Central Nervous, or Cranial Nerve Abnormalities\nImpairments in cognition, central nervous and cranial nerve function may indicate a brain metastasis. Oculo-\nsympathetic palsy (also called Horner's syndrome) \u2014 characterized by ptosis, miosis, anhidrosis, and\nenophthalmos \u2014 is associated with Pancoast tumors which invade the sympathetic nervous system, although\nthe deficit may also be caused by tumors of the brain and spine. Cognitive, central nervous, or cranial nerve\nabnormalities should lead to routine brain imaging, magnetic resonance imaging (MRI) of the brachial plexus,\nand computed tomography (CT) with intravenous (IV) contrast to evaluate the subclavian vessels. Central\nnervous abnormalities suggest stage IV disease. Invasion of the sympathetic nervous system represents T3\ndisease.\nPeripheral Muscle Weakness or Sensory Deficits\nAbnormalities of peripheral sensation and motor function may indicate a brain or spinal cord metastasis or tumor\ninvasion into peripheral nerves such as the brachial plexus (C5-T1 moto-sensory abnormalities) or\nintercostobrachial nerve (T2 distribution abnormality resulting in numbness of the inner arm). Peripheral muscle\nweakness or sensory deficits should lead to brain imaging and MRI of the brachial plexus to rule out brain\nmetastases or direct tumor invasion into peripheral nerves. Beyond staging, a thorough physical exam may\nimpact treatment decisions. Brain and spinal abnormalities may represent stage IV disease. Peripheral nerve\nabnormalities suggest T3 or T4 disease.\nJugular Venous Distension\n11, 12", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841624", "page": 18, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 3085}}
{"chunk_id": "tnm_lung_chunk_55", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n19/60", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841626", "page": 19, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 169}}
{"chunk_id": "tnm_lung_chunk_56", "text": "11/8/25, 11:55 AM\n\nDistention of the neck veins may be caused by lymphadenopathy obstruction in the neck, thoracic inlet, or\nmediastinum, superior vena cava (SVC) syndrome, or pericardial effusion. SVC syndrome may have other\nassociated physical examination findings such as facial and/or arm swelling, collateral cutaneous veins,\ncyanosis, and vision impairments. Pericardial effusion may have other associated clinical examination findings\nsuch as hypotension and muffled heart sounds (also known as Beck's triad). Jugular venous distension should\nlead to CT of the chest with IV contrast and possibly echocardiography. Distended neck veins caused by\nlymphadenopathy in the neck or mediastinum correlate to stage IV and III disease, respectively. A malignant\npericardial effusion represents stage IV disease.\nDysphonia (Hoarseness)\nDysphonia may be due to lymphadenopathy and/or direct tumor invasion of the recurrent laryngeal nerves. The\nleft recurrent laryngeal nerve is more often affected, although the right or even more rarely both recurrent\nlaryngeal nerves may be affected by bulky cervical or mediastinal lymphadenopathy. Direct laryngoscopy allows\nfor confirmation of vocal cord dysfunction. Dysphonia should lead to a CT of the chest with IV contrast.\nDysphonia from recurrent laryngeal nerve dysfunction may be due to compression or direct invasion. If the\ninvasion is by the primary tumor, it is T4. If it is by lymph node compression, then the dysphonia is caused by\nlymph node disease (N2 or N3 depending on primary tumor location). When it is impossible to determine if a\ntumor mass invading hilar/mediastinal structures represents the primary tumor or involved lymph nodes, it is\nreasonable to use the T category, together with an appropriate N category.\nLymphadenopathy\nLymphadenopathy in the neck and supraclavicular region may indicate nodal metastases. Although nodal\nmetastases may cause axillary and inguinal lymphadenopathy, it is far less common, especially if there is no\ncervical or supraclavicular lymphadenopathy. Lymphadenopathy should prompt a CT of the chest with IV contrast\nto characterize its extent. Palpable lymphadenopathy is amenable to fine or core needle biopsy and excisional\nbiopsy. Cervical (above the cricoid) and supraclavicular lymphadenopathy caused by lung cancer represents M1\nand N3, respectively.\nStridor or Wheezing\nStridor or wheezing may be caused by airway obstruction from a tumor or enlarged lymph node invading the\nairway or by causing extrinsic compression of the airway. Wheezing is more common than stridor, which is\ntypically associated with tracheal tumors, though wheezing is also associated with underlying chronic obstructive\nlung disease. Stridor and wheezing should lead to a CT of the chest with IV contrast to evaluate for causes of\nairway obstruction. Flexible bronchoscopy can aid in distinguishing extrinsic compression from direct invasion.\nDirect invasion of a mainstem bronchus is T2 disease, carinal or tracheal invasion is T4 disease.\nDiminished Breath Sounds\nDiminished breath sounds may be caused by airway obstruction with associated atelectasis, pleural effusion,\nlarge space occupying tumor, or an elevated hemidiaphragm. This finding should lead to a CT of the chest with\nIV contrast to evaluate potential etiologies. Atelectasis from airway obstruction is consistent with T2 disease.\nPleural effusion confirmed to be malignant represents stage IV disease. A large tumor leading to diminished\nbreath sounds is consistent with a T3 or T4 tumor. An elevated diaphragm may occur because a tumor or lymph\nnode metastasis has compressed or invaded the ipsilateral phrenic nerve. Phrenic nerve involvement represents\nT3 disease.\nAbdominal Organomegaly\nA palpable liver may arise from hepatic metastasis, underlying liver disease, or both. Although less common,\nmetastasis to the spleen can result in splenomegaly. Palpable abdominal organomegaly should be further\nevaluated with an abdominal ultrasound, CT of the abdomen with IV contrast, or MRI of the abdomen with and\nwithout contrast.\nCutaneous Lesion, Soft Tissue Mass, or Bony Tenderness\n13", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841629", "page": 19, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 4130}}
{"chunk_id": "tnm_lung_chunk_57", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n20/60", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841631", "page": 20, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 169}}
{"chunk_id": "tnm_lung_chunk_58", "text": "11/8/25, 11:55 AM\n\nAlthough rare, lung cancer can metastasize to skin or soft tissue. Inspection of a new skin lesion temporally\nassociated with suspicion for, or a diagnosis of lung cancer should be considered for biopsy, as should a new,\npalpable soft tissue mass. Bone pain or tenderness may increase suspicion of bone metastasis with a lytic\ncomponent prompting imaging with x-ray or CT for further characterization.\nNote I: Imaging\nThere are many imaging techniques and invasive procedures that may be used to diagnose and stage lung\ncancer. Whenever possible, they should be performed sequentially.\nThe IASLC recommends a three-step protocol to rationalize the use of staging procedures. Step I includes\nmedical history and physical examination, as well as plain radiographs of the chest and blood tests (complete\nblood count (CBC), alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, calcium, and\nalbumin). Step II includes more complex investigations, such as contrast-enhanced CT scan of the chest and\nupper abdomen, bone scan, PET scan, brain CT or MRI with contrast (except when contraindicated), and\nbronchoscopy. Step III includes the more invasive procedures, including surgical exploration of the mediastinum\n(mediastinoscopy, extended cervical mediastinoscopy, mediastinotomy, video-assisted mediastinal\nlymphadenectomy, transcervical extended mediastinal lymphadenectomy), the pleural space (thoracentesis,\npercutaneous needle biopsy, thoracoscopy, video-assisted thoracoscopic surgery), or the pericardium\n(pericardiocentesis, pericardioscopy).\nPosteroanterior and lateral chest radiography may be the first imaging technique requested for a patient with\nsuspected lung cancer. The minimal information to be extracted from chest X-rays is:\na. Tumor size (to assign a T category based on size)\nb. Lobar and segmental location of the tumor\nc. Presence of atelectasis and its extent (lobar or complete; cT2)\nd. Presence of separate tumor nodules (cT3, cT4, or cM1a)\ne. Evidence of lymphangitic carcinomatosis (cLy0: no radiologic evidence of lymphangitic carcinomatosis; cLy1:\nradiologic evidence of lymphangitic carcinomatosis confined to the area of the primary tumor; cLy2:\nlymphangitic carcinomatosis at a distance from the primary tumor but confined to the same lobe; cLy3:\npresence of lymphangitis in other ipsilateral lobes; cLy4: lymphangitis affecting the contralateral lung)\nf. Relation of the primary tumor to the chest wall (contact or bone destruction [cT3]) or the mediastinum (elevated\ndiaphragm may indicate invasion of the phrenic nerve [cT3])\ng. Nodal spread: enlarged hilum and abnormal mediastinum may indicate cN1, or cN2, disease\nh. Intrathoracic spread: the presence of pleural or pericardial effusions (cM1a)\ni. Extrathoracic spread: the integrity or involvement of the bones visible on chest X-rays \u2014 the ribs, the sternum,\nboth scapulae, the vertebral column, the shoulder joint, and most of the length of both humeri; masses in the\nsoft tissues of the chest wall (cM1b or cM1c)\nContrast CT of the chest and upper abdomen to include the liver and both adrenal glands is recommended for\npatients with proven or suspected lung cancer who are eligible for treatment.\nCT of the chest should confirm,\nrefine and build on the information obtained from the chest X-rays:\na. Tumor size in its greatest dimension, which is usually assessed by measuring the maximum tumor size on\naxial images; coronal and sagittal images can be used to assess the tumor size, if technically possible.\nTherefore, all the different projections should be evaluated to determine the tumor size. Lung CT window\ndisplay settings should be used when assessing images for tumor size. Total tumor size including ground glass\nand solid tumor should be measured and reported. The solid component should be reported in addition to the\n14\n15", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841634", "page": 20, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 3870}}
{"chunk_id": "tnm_lung_chunk_59", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n21/60", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841636", "page": 21, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 169}}
{"chunk_id": "tnm_lung_chunk_60", "text": "11/8/25, 11:55 AM\n\ntotal tumor size and determines the T category in part solid tumors. In tumors with multiple solid areas\ninterspersed within the ground glass components, each of the solid areas should be measured separately and\nadded to get a total solid component that will determine the T category. (Figure Lung-AAH) (Figure Lung-\nAdenocarcinoma (cTis, cT1mi, cT1a, cT1b, cT1c))\nb. Lobar and segmental location\nc. Presence of atelectasis (partial or total; cT2) and endobronchial lesions. Whenever possible the extent of\ninvasion of the mediastinal organs should be reported.\nd. Presence of separate solid tumor nodules in the same lobe and other lobes should be reported (possibly cT3,\ncT4, or cM1a). The morphology of the separate tumor nodules should be described wherever possible, and\neffort should be made to describe if the separate tumor nodules are morphologically similar to the primary\ntumor. Additional details regarding multiple tumor nodules are described in the Multiple Tumors section.\ne. Nodal spread: hilar enlargement suggests cN1 disease if it is ipsilateral to the primary tumor or cN3 disease if\nit is contralateral nodal involvement. Nodes should be measured on mediastinal windows using a\nbidimensional caliper and the short-axis diameter of \u2265 10 mm and abnormal nodal morphology (loss of hilar fat\nand or enhancement on post-contrast images) should be used to determine if a node is potentially metastatic\nfor clinical N categorization.\nf. FDG PET/CT- Increased nodal FDG uptake at a similar level to that of the primary tumor in addition to\nincreased size and suspicious morphology can be used to identify clinically involved lymph nodes. Involved\nmediastinal lymph nodes (FDG avid) may indicate cN2 disease if they are ipsilateral or subcarinal or cN3\ndisease if they are contralateral or supraclavicular. The number of nodal stations involved should be\ndetermined. Involvement of a single ipsilateral mediastinal or the subcarinal station indicates N2a, multiple\nipsilateral (including the subcarinal) lymph node stations indicate N2b. Mediastinal CT window display settings\nshould be used when assessing images for mediastinal structures, pleural or pericardial effusions, etc. Note\nshould be made that if the SUV\nof the tumor is close to background, the involved nodes may also have\nuptake similar to background or blood pool.\ng. Evidence of lymphangitic carcinomatosis (cLy0, cLy1, cLy2, cLy3, and cLy4 as defined earlier)\nh. Intrathoracic spread: pleural and pericardial effusion/pleural thickening or nodules (cM1a)\ni. Extrathoracic spread: bone lesions, soft tissue masses, adrenal masses, and liver lesions may indicate cM1b\ndisease if single, cM1c1 disease if multiple in the same organ system, and cM1c2 disease if involving multiple\norgan systems.\nFigure Lung-Imaging Atypical Adenomatous Hyperplasia (AAH). 5 mm pure ground glass nodule in the right\nmiddle lobe (in white box); schematic drawing showing pure ground glass nodule measuring 5 mm; pathology\nproven atypical adenomatous hyperplasia (AAH); incidental part solid invasive adenocarcinoma in the right upper\nlobe.\nFigure Lung-Imaging Adenocarcinoma in Situ (cTis). 8 mm pure ground glass nodule in the left upper lobe\n(white box); schematic drawing showing pure ground glass nodule measuring 8 mm, compatible with\nadenocarcinoma in situ cTis; pathologic examination of the resected specimen confirmed the suggested clinical\ndiagnosis.\nmax", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841639", "page": 21, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 3443}}
{"chunk_id": "tnm_lung_chunk_61", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n22/60", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841642", "page": 22, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 169}}
{"chunk_id": "tnm_lung_chunk_62", "text": "11/8/25, 11:55 AM\n\nFigure Lung-Imaging Minimally Invasive Adenocarcinoma (cT1mi). 10 mm part solid nodule in the left upper\nlobe with a 5 mm solid component (white box) compatible with minimally invasive adenocarcinoma (MIA) cT1mi;\nschematic drawing showing 10 mm total tumor (solid + ground glass component); solid (white) 5 mm determines\nthe invasive component and the cT category of cT1mi. Pathologic examination of the resected specimen confirmed\nthe suggested clinical diagnosis.\nFigure Lung-Imaging Invasive Adenocarcinoma (cT1a). 10 mm part solid nodule in the right lower lobe with an 8\nmm solid component (white box); schematic drawing showing 10 mm total tumor (solid + ground glass component);\nsolid (white) 8 mm determines the invasive component and the cT category of cT1a.\nFigure Lung-Imaging Invasive Adenocarcinoma (cT1b). 15 mm part solid nodule in the right lower lobe with 12\nmm solid component (white box); schematic drawing showing 15 mm total tumor (solid + ground glass component);\nsolid (white) 12 mm determines the invasive component and the cT category of cT1b.\nFigure Lung-Imaging Invasive Adenocarcinoma (cT1c). 29 mm part solid nodule in the right lower lobe with a 22\nmm solid component (white box); schematic drawing showing 29 mm total tumor (solid + ground glass component);\nsolid (white) 22 mm determines the invasive component and the cT category of cT1c.\nCT of the chest with contrast is important for assessing the size and location of any enlarged mediastinal and\nhilar lymph nodes (lymph nodes greater than 10 mm in short axis are deemed positive by imaging, nodes\nmeasuring 10 mm or with suspicious morphology and enhancement in stations such as internal mammary are\nconsidered suspicious), because in the absence of metastasis, they are the strongest indicators of prognosis. In\na review of 7,368 patients with a median prevalence of mediastinal nodal disease of 30%, staging values of\nchest CT were as follows: sensitivity, 0.55; specificity, 0.81; positive predictive value, 0.58; and negative\npredictive value, 0.83.\n18-FDG PET/CT is indicated in patients who are candidates for treatment with curative intent. It is useful for\nevaluating metastatic spread, except that occurring in the brain. PET is not required in patients with ground-glass\nopacities or clinical stage IA tumors with no other abnormality on CT of the chest. Regarding mediastinal staging,\nin a review of 4,105 patients with a median prevalence of nodal disease of 28%, staging values were as follows:\nsensitivity, 0.8; specificity, 0.88; positive predictive value, 0.75; and negative predictive value, 0.91.\nPET should\nprovide the following information:\na. Presence of normal or abnormal uptake in the primary tumor and quantification by maximum standardized\nuptake value (SUV\n)\nb. Presence of normal or abnormal uptake in hilar, mediastinal and distant nodes and quantification by SUV\nc. Presence of normal or abnormal uptake in other parts of the lungs or other sites of metastases in the rest of\nthe body\nAlthough SUV\nis subject to many intra- and inter-institutional variations, it is important to record it at initial\nstaging to assess metabolic tumor response after treatment, especially after induction treatment to evaluate the\npossibility of tumor resection. SUV\nalso has shown prognostic value, at least for Stage I-III squamous cell\ncarcinomas and adenocarcinomas.\nBecause PET has a poor anatomic resolution, the superimposition of PET with CT (e.g., with hybrid PET/CT\nscanners) may help the clinician locate the lesions with abnormal uptake. However, the mean staging values of\n15\n15\nmax\nmax\nmax\nmax\n16", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841644", "page": 22, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 3631}}
{"chunk_id": "tnm_lung_chunk_63", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n23/60", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841647", "page": 23, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 169}}
{"chunk_id": "tnm_lung_chunk_64", "text": "11/8/25, 11:55 AM\n\ncombined PET/CT are similar to those of PET alone. In a review of 2,014 patients with a median prevalence of\nmediastinal nodal disease of 22%, the staging values for combined PET/CT were as follows: sensitivity, 0.62;\nspecificity, 0.9; positive predictive value, 0.63; and negative predictive value, 0.9.\nThe positive predictive value of PET is relatively low; therefore, histopathological confirmation of the lesions is\nrecommended if this will affect therapy. Inflammations, granulomas, and infections may have high SUV\n, and if\nthe correct histology remains unconfirmed, the patient may be erroneously excluded from radical treatment. If\nPET is not available, a combination of bone scanning and abdominal CT should be done to rule out metastatic\nspread.\nMagnetic resonance (MR) imaging has very specific indications in lung cancer staging. MR imaging of the brain\ncurrently is indicated in patients with stage III and IV tumors, even if they have a negative clinical evaluation.\nIt\nalso is indicated in patients with brain metastasis identified on CT, as MR imaging has higher sensitivity than CT\nand may identify smaller and additional lesions.\nMR of the chest and brachial plexus also may help define the\ninvolved anatomic structures in patients with apical (Pancoast) tumors or tumors invading the chest wall and\nmediastinum. MR imaging of the adrenals with chemical shift (in- and out-of-phase imaging) may help exclude\nadrenal metastases by identifying lipid-poor adenomas which may present as indeterminate adrenal lesions\n(variable FDG avidity) on PET/CT.\nThe order in which the aforementioned anatomic and metabolic imaging tests are performed may be chest X-\nrays first, followed by CT scan of the chest and upper abdomen with contrast, 18 FDG PET/CT scan, CT of the\nhead with contrast, and/or MR imaging of the brain with contrast and MR of the chest or brachial plexus in\nindicated cases.\nThe anatomic and metabolic imaging techniques described here provide a thorough description of the primary\nlesion and its local and distant spread, but do not provide its diagnosis. The TNM classification requires\nmicroscopic confirmation of malignancy\nand specification of histopathological type.\nThe type of procedure\nused to obtain pathological confirmation of lung cancer differs depending on the location and spread of the\ntumor.\nSputum cytology may provide the diagnosis of lung cancer with high specificity. In a review of 29,145 patients,\nthe diagnostic values of sputum cytology were as follows: sensitivity, 0.66; specificity, 0.99; false positive rate,\n8%; and false negative rate, 10%.\nIn certain patients with evident metastatic disease, this may be the only\ndiagnostic test needed. However, molecular profiling of tumors is best performed on cell blocks; if these are not\navailable in the sputum specimen, then larger samples may be needed.\nFiberoptic bronchoscopy is both a diagnostic and a staging procedure. As a diagnostic procedure including\nbronchial biopsy, brushings, washings, and endobronchial and transbronchial needle aspiration, its sensitivity is\n0.88 and 0.78 for central and peripheral tumors, respectively.\nAs a staging procedure, it shows the\nendobronchial location of the tumor: T2 if the main bronchus is involved, regardless of its distance to the carina,\nand T4 if the carina is involved. It may suggest nodal involvement if there is extrinsic compression of the bronchi.\nThe lymph nodes may be punctured with fine needles, either blindly with the classic transbronchial needle\naspiration (TBNA) procedure, with the assistance of EBUS and transbronchial needle aspiration (EBUS-TBNA),\nendoscopic ultrasonography (EUS) and fine needle aspiration (FNA) (EUS-FNA). Peripheral tumors that remain\nundiagnosed by fiberoptic bronchoscopy may be diagnosed by transthoracic needle aspiration or biopsy, with a\nsensitivity of 0.9, a specificity of 0.97, a false positive rate of 1%, and a false negative rate of 22%.\nThoracentesis and cytopathologic study of the pleural fluid may be enough in patients with malignant pleural\neffusion. It provides a diagnosis in 72% of patients.\nIf cytology is negative, further pleural explorations with\nclosed pleural biopsy and thoracoscopy should follow. Sensitivity and negative predictive values are both\napproximately 80% for closed pleural biopsy and greater than 80% and approximately 100%, respectively, for\nthoracoscopic biopsy.\nA malignant pleural effusion or tumor nodules on the pleural surface (parietal or visceral)\nclassify the tumor as M1a. Thoracoscopy has the advantage of allowing exploration of the pleural cavity, lung\n15\nmax\n15\n15\n17\n18, 19\n10\n20\n20\n20\n20\n20", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841649", "page": 23, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 4666}}
{"chunk_id": "tnm_lung_chunk_65", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n24/60", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841652", "page": 24, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 169}}
{"chunk_id": "tnm_lung_chunk_66", "text": "11/8/25, 11:55 AM\n\nsurface, and mediastinum. Video-assisted thoracoscopic surgery also allows resection of peripheral nodules and\nassists in their diagnosis and staging. Ipsilateral hilar and mediastinal nodes may be biopsied as well.\nThe American College of Chest Physicians (ACCP), the National Comprehensive Cancer Network (NCCN), and\nthe European Society of Thoracic Surgeons (ESTS) published guidelines on the preoperative staging of\nmediastinal lymph nodes.\nThe 2013 ACCP Evidence-based Clinical Practice Guidelines favor invasive\nstaging by needle aspiration techniques (EBUS-TBNA, EUS-FNA) as the first procedures, but recommend\nconfirmation with surgical biopsies (mediastinoscopy) if needle techniques are negative. NCCN allows for either\nan EBUS or mediastinoscopy first approach. In the absence of metastatic disease, the indications for invasive\nstaging are as follows\n:\na. Discrete mediastinal lymph node enlargement with or without FDG uptake in mediastinal lymph nodes on PET\nscan\nb. FDG activity in mediastinal lymph nodes on PET scan or abnormally enlarged lymph nodes on CT\nc. High suspicion of N2 or N3 disease, either by lymph node enlargement on CT or FDG uptake\nd. Intermediate suspicion of N2 or N3 disease by CT and PET and a central tumor or N1 (hilar) disease\ne. Tumors > 3cm\nInvasive staging is not indicated for patients with extensive mediastinal infiltration or peripheral, stage IA tumors\nwith no suspicion of mediastinal lymph node involvement on CT or PET.\nThe ESTS guidelines also recommend performing EBUS-TBNA and EUS-FNA as the initial exploration in the\nfollowing situations\n:\na. Positive mediastinal nodes on CT and/or PET or PET/CT\nb. Cases in which there is no evidence of N2-N3, but there is suspicion of N1 disease; central tumors larger than\n3 cm; and adenocarcinomas with high FDG uptake\nInvasive staging may be avoided in patients with no evidence of mediastinal disease on CT and PET and tumors\nless than 3 cm in greatest dimension located peripherally, that is, in the outer third of the lung.\nIf needle techniques produce negative results, video-assisted mediastinoscopy is recommended to confirm the\nresults or to identify mediastinal disease. In general, the negative predictive values of EBUS-TBNA and EUS-\nFNA are too low, both in patients with normal and those with abnormal mediastinal lymph nodes, to make\ntherapeutic decisions without proper confirmation by a surgical technique. In a recent article on the staging value\nof EBUS-TBNA in patients with no mediastinal abnormalities, the sensitivity and negative predictive values for\nEBUS-TBNA were 0.38 and 0.81, respectively, whereas they were 0.73 and 0.91 for mediastinoscopy.\nThis\narticle clearly highlights the importance of confirming negative results of EBUS-TBNA and EUS-FNA with\nmediastinoscopy. Recent evidence suggests that routine mediastinoscopy after negative EBUS may not be\nnecessary.\nHowever, these cases should be reviewed by a multi-disciplinary team.\nAdditionally, the ESTS guidelines recommend exploration of the aortopulmonary window for left lung cancers and\nestablish minimum requirements for mediastinoscopy in clinical practice: at least the inferior right and left\nparatracheal lymph nodes and the subcarinal lymph nodes should be biopsied or removed; the superior right and\nleft paratracheal lymph nodes and the hilar lymph nodes should be explored if there is evidence of involvement\non CT or PET.\nOther invasive procedures should be performed as required, including pericardiocentesis or pericardioscopy,\neither transpleural or subxiphoid, for pericardial effusion, needle biopsies of liver and adrenal lesions,\nendoscopies of the gastrointestinal tract in cases of digestive symptoms or bleeding, and biopsy or excision of\nskin lesions.\n15, 21\n15\n15\n21\n22\n23\n21", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841655", "page": 24, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 3801}}
{"chunk_id": "tnm_lung_chunk_67", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n25/60\n\nThese procedures should be performed sequentially from the least to most invasive: first, to rule out stage IV-\ndefining metastatic disease if imaging suggests metastatic spread, as this will avoid more invasive procedures;\nnext, to rule out supraclavicular nodal disease (N3) if there is anatomic or metabolic suspicion; and finally, to\nexplore the mediastinum as indicated by the aforementioned guidelines.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841657", "page": 25, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 577}}
{"chunk_id": "tnm_lung_chunk_68", "text": "Multiple Tumors\n\nThe clinical TNM stage is applied when a nodule or lesion has been diagnosed as lung cancer. The classification\nof lung cancers with multiple lesions can be problematic. This is due to the lack of tissue diagnosis or histological\nconfirmation of all lesions and/or absent or limited longitudinal follow-up, precluding determination whether the\nmultiple lesions are multiple primary tumors or metastases. The rules are sometimes ambiguous, and their\napplication may be interpreted differently by radiologists. Therefore, a special subcommittee of the IASLC\nStaging and Prognostic Factors Committee studied different presentations of multiple tumors and made some\nrecommendations regarding the uniform use of the classification rules depending on the pattern of disease. The\nsubcommittee established four disease patterns namely: a) two or more primary tumors - synchronous (present\nat the same time of diagnosis) and metachronous (appearing during follow up after treatment of the first tumor);\nb) lung cancers with separate tumor nodules of the same histopathological type in the same lobe and other\nlobes; c) multiple tumors with ground-glass and part solid features on CT and a lepidic pattern on pathological\nexamination; and d) diffuse pneumonic-type lung cancer presenting as consolidations mimicking pneumonia.\nThree in-depth articles expand the rationale for applying the classification rules to each disease pattern.\nIt is\nthe managing physician who determines, from the clinical, imaging and pathological information (usually after a\nmultidisciplinary discussion), to what pattern of disease the patient's tumor belongs to, and then, classifies\naccording to the recommendations stated below.\nThe recommendations for four classifications are as follows:\na. Two or More Primary Lung Cancers (Synchronous or Metachronous): Two or more synchronous or\nmetachronous primary tumors should be classified separately, with an individual TNM for each tumor,\nregardless of whether they are in the same lobe, same lung, or contralateral lung (Figure Lung-Two Primary\nLung Cancers (Synchronous)). This rule applies to tumors identified clinically or grossly and also to those\nidentified on pathological examination. Each tumor should be assigned a T category based on the maximum\nsolid component measured on axial images using lung windows on CT scans. The N category is assessed by\nmeasuring the short axis of the lymph node on mediastinal windows using the > 10 mm cut off to identify\npositive lymph nodes. The M category can be difficult to assess on a single time point as distinction between\nsynchronous tumors and metastasis may not be possible. In such circumstances prior scans or a repeat CT\nscan at 3-6 months may be needed to determine growth and/or development of additional nodules concerning\nfor metastasis.\nFigure Lung-Two Primary Lung Cancers (Synchronous). Two synchronous primary tumors: part solid right\nupper lobe tumor biopsy proven to be adenocarcinoma (cT1c); resected left upper lobe solid mass pathology\nproven to be a carcinosarcoma (pT1b). Separate T, N and M for each tumor.\nb. Separate Tumor Nodules of the Same Histopathologic Type (Intrapulmonary Metastases): These tumors\ncomprise of a dominant lesion in one lobe usually an advanced tumor or tumor with aggressive tumor biology\nand one or more additional nodules in the same lobe or other lobes deemed metastases based on morphology\nand growth rate. The classification of these tumors is based on their lobar location (Figure Lung-Primary\nAdenocarcinoma with Bilateral Intrapulmonary Metastases: cT4 cN1 cM1a). If the separate tumor nodule(s)\nis(are) in the same lobe of the primary, the tumor is classified as T3. If the separate tumor nodule(s) is(are) in\nanother ipsilateral lobe, the tumor is classified as T4. The tumor classification is M1a if the separate tumor\nnodule(s) is(are) in the contralateral lung. This classification applies to separate tumor nodules identified\n24-26\n25", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841660", "page": 26, "cancer_type": "Lung", "category": "Unknown", "section": "Multiple Tumors", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 3984}}
{"chunk_id": "tnm_lung_chunk_69", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n26/60", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841663", "page": 26, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 169}}
{"chunk_id": "tnm_lung_chunk_70", "text": "11/8/25, 11:55 AM\n\nclinically or grossly and also to those identified microscopically on pathological examination.\nMiliary\nmetastases described as numerous lung nodules less than 2 mm in all lobes of the lung are classified as M1a.\nFigure Lung-Primary Adenocarcinoma with Bilateral Intrapulmonary Metastases: cT4 cN1 cM1a. Primary\nlung cancer in the right lower lobe measuring 4.2 cm, with a right hilar lymph node and multiple separate tumor\nnodules of the same radiographic morphology suggestive of intrapulmonary metastases; cT4 cN1 cM1a.\nc. Multifocal Lung Adenocarcinomas with Ground-Glass/Lepidic Features: These tumors should be\nclassified by the T category of the dominant lesion (lesion with the largest solid component) (Figure Lung-\nMultifocal Lung Adenocarcinoma with Ground-Glass/Lepidic Features), with the highest T followed by the\nnumber of lesions (#) indicated in parentheses. In the event of numerous nodules, an attempt should be made\nto count the nodules and the word numerous or greater than 10 nodules in all lobes of lung may be used. The\nT category should be determined by the largest diameter of the solid component (representing invasive\ncomponent on pathological examination) using lung windows on CT scan. The total size including the ground\nglass component should be reported, in order to plan for and allow complete surgical resection, especially in\nsublobar resections. In cases where there are multiple small solid components within the tumor, the solid areas\ncan be measured separately and added to determine the total solid component representing the T category.\nThe T(#/m) multifocal classification should be applied whether the lesions are in the same lobe or in different\nipsilateral or contralateral lobes. The multiple lesions may be described as adenocarcinoma spectrum lesions\nbased on varying degrees of solid component often less than 5 mm (Figure Lung-Primary Adenocarcinoma\nand Multifocal Adenocarcinoma). These are very slow-growing lesions and the ground glass component most\nlikely represents lepidic features on pathology. Furthermore, this classification should be applied to grossly\nrecognizable lesions as well as to lesions discovered only on microscopic examination. Note should be made it\nis relatively rare to have nodal involvement in these tumors.\nFigure Lung-Multifocal Lung Adenocarcinoma with Ground-Glass/Lepidic Features. Multifocal lung\nadenocarcinomas with ground-glass/lepidic features, several part solid nodules with varying size of the solid\ncomponent, all lesions growing slowly over the last 5 years: Multifocal adenocarcinoma. Clinical stage is designated\nby the largest lesion, in this case the left lower lobe nodule measuring 1.3 cm - cT1b(m) and multiple nodules are\npresumed to be adenocarcinoma spectrum lesions. (Single N and M for all lesions collectively).\nFigure Lung-Primary Adenocarcinoma and Multifocal Adenocarcinoma. Part solid right upper lobe tumor\nbiopsy proven to be adenocarcinoma (cT1c(m)); multiple bilateral ground glass and part solid opacities in the right\nmiddle lobe and left upper lobe concerning for adenocarcinoma spectrum lesions. (Single N and M for all lesions\ncollectively).\nd. Diffuse Pneumonic-Type Adenocarcinoma: These tumors have the appearance of consolidation with or\nwithout ground glass component and are often initially misdiagnosed as pneumonia. These tumors have been\nassociated with bronchorrhea and often have one area of dominant consolidation and additional smaller areas\nof pure ground glass nodules and/or part solid ground glass nodules in the same lobe or other lobes of the\nlung. The consolidative opacity may not have clearly defined borders. Effort should be made to measure the\nlargest axial dimension of the consolidative opacity using lung windows on CT scan. In the case of a single\ntumor area, a standard TNM classification based on tumor size, nodal disease, and metastasis should be\napplied. In cases of multiple tumor areas, the T and M categories should be based on the location of the\ninvolved areas: T3 if the disease is confined to one lobe, T4 if it involves other ipsilateral lobes, and M1a if it\ninvolves the contralateral lung (Figure Lung-Diffuse Pneumonic-Type Adenocarcinoma: cT4 cN0 cM1a). If an\n24\n26", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841665", "page": 26, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 4253}}
{"chunk_id": "tnm_lung_chunk_71", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n27/60\n\narea of involvement extends to the adjacent lobe, a T4 category should be assigned to recognize the\nextension into another ipsilateral lobe. If the tumor is confined to one lobe but its size is difficult to measure, a\nT3 category should be assigned. The N category is selected to apply to all pulmonary sites of the primary\ntumor collectively. Pleural/pericardial tumor nodules or distant metastases will lead to an M1a, M1b, or M1c\ndesignation. The classification should be applied to grossly recognizable lesions as well as to lesions\ndiscovered only on histologic examination.\nFigure Lung-Diffuse Pneumonic-Type Adenocarcinoma: cT4 cN0 cM1a. Multifocal pneumonia like\nconsolidations, biopsy proven to be adenocarcinoma (wedge resection in left lower lobe). The cT category is\ndefined by the largest consolidation lesion in one lobe; T4 is two or more lobes in the same lung and M1a is\ncontralateral lung involvement. Since there are bilateral consolidations the clinical classification and stage for the\nabove tumor is cT4 cN0 cM1a and stage IVA.\nThe aforementioned recommendations for classifying the different patterns of disease are the result of a\nmultidisciplinary and international consensus as well as a thorough literature review and statistical analysis of\ndata from the IASLC database regarding separate tumor nodules. These suggestions are meant to minimize\nambiguity and to serve as a guide in classifying these tumors uniformly.\nTable Lung-Clinical Criteria (4 tables) below describe the clinical criteria used to define the different disease\npatterns in which lung cancers with multiple lesions may present.\nTable. Lung-Clinical Criteria to Distinguish Second Primary Versus Related Tumors\n*\nTable. Lung-Clinical Criteria to Categorize a Lesion as a Separate Tumor Nodule (Intrapulmonary Metastasis)\nTable. Lung-Clinical Criteria to Categorize a Tumor as Multifocal GG/L Adenocarcinoma\nTable. Lung-Clinical Criteria to Categorize a Tumor as Pneumonic-Type Adenocarcinoma\nPathological classification of lung cancers with multiple lesions follows the same criteria recommended for\nclinical classification of the four different patterns of disease: separate primary tumors, separate tumor nodules\n(intrapulmonary metastasis), ground-glass/lepidic adenocarcinomas, and pneumonic-type adenocarcinomas.\n26\n25\n24\n26\n26\n27", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841668", "page": 27, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 2500}}
{"chunk_id": "tnm_lung_chunk_72", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n28/60\n\nTable Lung-Pathological Criteria (4 Tables) below describe the pathological criteria for defining the different\ndisease patterns in which lung cancers with multiple lesions may present.\nTable. Lung-Pathological Criteria (i.e., After Resection) for Separate Versus Related Pulmonary Tumors\nTable. Lung-Pathological Criteria to Categorize a Lesion as a Separate Tumor Nodule (Intrapulmonary\nMetastasis)\nTable. Lung-Pathological Criteria Identifying Multifocal Ground-Glass/Lepidic Lung Adenocarcinoma\nTable. Lung-Pathological Criteria Identifying Pneumonic-Type Adenocarcinoma\nTable. Lung-Summary of Disease Patterns and TNM Classification of Patients with Lung Cancer with Multiple\nPulmonary Sites of Involvement\nIntroduction to TNM Staging Classification\nStage may be defined at several time points in the care of the patient with cancer. To properly stage a patient's\ncancer, it is essential to first determine the time point in a patient's care. These points in time are termed\nclassifications and are based on time during the continuum of evaluation and management of the disease. Then,\nT, N, and M categories are assigned for a particular classification (clinical, pathological, posttherapy, recurrence,\nand/or autopsy) by using information obtained during the relevant time frame, sometimes also referred to as a\nstaging window. These staging windows are unique to each particular classification and are set forth explicitly in\nthe Supplemental Information. The prognostic stage groups then are assigned using the T, N, and M categories,\nand sometimes also site-specific prognostic and predictive factors.\nAmong these classifications, the two predominant are clinical classification (i.e., pretreatment) and pathological\nclassification (i.e., after surgical treatment as initial therapy).\nNote C: Rules for Clinical TNM Classification\nClinical stage classification is based on patient history, physical examination, and any imaging done before\ninitiation of treatment. Imaging study information may be used for clinical staging, but clinical stage may be\nassigned based on whatever information is available. No specific imaging is required to assign a clinical stage for\nany cancer site. When performed within this framework, biopsy information on regional lymph nodes and/or other\nsites of metastatic disease may be included in the clinical classification. The TNM is denoted by use of a\n25\n24\n26\n26\n27", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841670", "page": 28, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 2577}}
{"chunk_id": "tnm_lung_chunk_73", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n29/60", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841673", "page": 29, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 169}}
{"chunk_id": "tnm_lung_chunk_74", "text": "11/8/25, 11:55 AM\n\nlowercase c prefix: cT, cN, and cM0, cM1, or pM1. The M category use of cM or pM is based on method of\nassessment.\nSee General Staging Rules Table and Stage Classifications Table in Supplemental Information for additional\nguidance, including the time frame/staging window for determining clinical stage.\nClinical stage is important to record for all patients because:\n\u2022 clinical stage is essential for selecting initial therapy, and\n\u2022 clinical stage is critical for comparison across patient cohorts when some have surgery as a component of initial\ntreatment and others do not.\nClinical stage may be the only stage classification by which comparisons can be made across all patients,\nbecause not all patients will undergo surgical treatment before other therapy, and response to treatment varies.\nDifferences in primary therapy make comparing groups of patients difficult if that comparison is based on\npathological assessment. For example, it is difficult to compare patients treated with primary surgery with those\ntreated with chemotherapy or radiation therapy without surgery or neoadjuvant therapy.\nClinical classification is based on evidence acquired from the date of diagnosis until initiation of primary\ntreatment. Examples of primary treatment include definitive surgery, radiation therapy, systemic therapy, and\nneoadjuvant radiation and systemic therapy.\nClinical Classification\nClinical classification or pretreatment clinical classification, cTNM, is essential for selecting and evaluating\ntherapy. It is based on the evidence found before treatment, including the results of history and physical\nexamination, imaging studies (e.g., computed tomography [CT] and positron emission tomography [PET]),\nlaboratory tests, and staging procedures such as bronchoscopy or esophagoscopy with or without ultrasound-\nguided biopsy (e.g., endobronchial ultrasound-transbronchial needle aspiration [EBUS-TBNA] or endoscopic\nultrasound-fine needle aspiration [EUS-FNA]), mediastinoscopy, mediastinotomy, extended cervical\nmediastinoscopy, thoracentesis, pleural biopsy, pericardioscopy, thoracoscopy, and video-assisted thoracoscopic\nsurgery (VATS), as well as exploratory thoracotomy.\nNote P: Rules for Pathological TNM Classification\nClassification of T, N, and M after surgical treatment is denoted by use of a lowercase p prefix: pT, pN, and cM0,\ncM1, or pM1. The purpose of pathological classification is to provide additional precise and objective data for\nprognosis and outcomes, and to guide subsequent therapy.\nPathological stage classification is based on clinical stage information supplemented/modified by operative\nfindings and pathological evaluation of the resected specimens. This classification is applicable when surgery is\nperformed before initiation of adjuvant radiation or systemic therapy.\nSee General Staging Rules Table and Stage Classifications Table in Supplemental Information for additional\nguidance.\nPathological Classification\nPathological classification or postsurgical classification, pTNM, is used to guide adjuvant therapy and provides\nuseful information to estimate prognosis and calculate end results. It is based on evidence acquired before\ntreatment, supplemented or modified by additional evidence acquired from surgery and from pathological\nexamination of the resected specimens.\nRegarding tumors that underwent an attempt at resection but were not removed completely, the AJCC and UICC\nagree on when to consider pathological classification.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841675", "page": 29, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 3503}}
{"chunk_id": "tnm_lung_chunk_75", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n30/60", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841678", "page": 30, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 169}}
{"chunk_id": "tnm_lung_chunk_76", "text": "11/8/25, 11:55 AM\n\na. Microscopic confirmation of highest T and highest N categories or\nb. Microscopic confirmation of M1\nAlthough AJCC and UICC set the rules on staging, the ACCP recommends the use of the p prefix for resected\ntumors, as well as for the rare cases in which a tumor was not resected, but extensive biopsy samples were\ntaken during the resection attempt. In the clinical staging context, even if there is pathological confirmation of\ntumor extent, the c prefix should be used.\nThe International Association for the Study of Lung Cancer endorses\nthis recommendation.\nNote YC: Rules for Posttherapy Clinical TNM Classification\nStage determined after treatment for patients receiving systemic and/or radiation therapy alone or as a\ncomponent of their initial treatment, or as neoadjuvant therapy before planned surgery, is referred to as\nposttherapy classification. It also may be referred to as post neoadjuvant therapy classification.\nSee General Staging Rules Table and Stage Classifications Table in Supplemental Information for additional\nguidance.\nObserved changes between the clinical classification and the posttherapy classification may provide clinicians\nwith information regarding the response to therapy. The clinical extent of response to therapy may guide the\nscope of planned surgery, and the clinical and pathological extent of response to therapy may provide prognostic\ninformation and guide the use of further adjuvant radiation and/or systemic therapy.\nClassification of T, N, and M after systemic or radiation treatment intended as definitive therapy is denoted by\nuse of a lowercase yc prefix: ycT, ycN, c/pM. The c/pM category may include cM0, cM1, or pM1. The posttherapy\nclinical assessment of the T and N (ycTNM) categories uses specific criteria. In contrast, the M category for post\nneoadjuvant therapy classification remains the same as that assigned in the clinical stage before initiation of\nneoadjuvant therapy (e.g., if there is a complete clinical response to therapy in a patient previously categorized\nas cM1, the M1 category is used for final yc and yp staging).\nSee Stage Classifications Table in Supplemental Information for additional guidance.\nPosttherapy Clinical Classification\nAfter initial primary systemic and/or radiation therapy has been completed, assessment for response to treatment\nis conducted with either a contrast enhanced CT of the chest and abdomen or with a PET/CT. The assessment\nbased on physical examination, imaging, and potentially biopsies is assigned a posttherapy clinical stage\n(ycTNM). The ycT is assigned for any residual primary tumor or ycT0 for no residual tumor. The determination of\npost treatment clinical stage is based on maximum size of the residual tumor on CT scan and is compared with\nthe baseline scan pre-treatment to assess response to therapy using RECIST 1.1 or iRECIST 1.1 based on the\ntype of neoadjuvant therapy used. In the case of PET/CT, the SUV\nof the post treatment tumor is compared\nwith the baseline scan and the response is categorized based on change in size and SUV\nof the residual\ntumor. If a tumor was radiated it may be difficult to distinguish between radiation fibrosis and residual tumor and\nthe SUV\nis equal to or less than the background activity, a complete response by PET/CT is assigned.\nHowever, sometimes false positive uptake may be seen on PET/CT due to inflammation, a multidisciplinary\ndiscussion is often needed to determine resectability. Of note pleurodesis can lead to varying degrees of uptake\non PET/CT in the pleura for long periods of time and may also need a multidisciplinary discussion. The ycN is\nassigned for the nodal status. Similar to T category, both size and SUV\nof the nodes is reassessed after\ntherapy and compared with baseline to upstage or downstage. The M category is the same as that assigned\n(cM0, cM1, or pM1) in the clinical stage, regardless of the patient's response to therapy. For example, a tumor\ncategorized as cM1 before therapy will be categorized as cM1 for the final yc staging even if it had a complete\nclinical response to therapy.\n28\n13\nmax\nmax\nmax\nmax", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841680", "page": 30, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 4124}}
{"chunk_id": "tnm_lung_chunk_77", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n31/60", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841683", "page": 31, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 169}}
{"chunk_id": "tnm_lung_chunk_78", "text": "11/8/25, 11:55 AM\n\nFor patients receiving induction therapy, posttherapy clinical staging should include mediastinal lymph node\nevaluation, either via mediastinoscopy or endobronchial ultrasound (EBUS), and CT +/- FDG-PET/CT. If there is\nsurgical resection performed, information from that surgical resection is assigned posttherapy pathological stage,\nypTNM (Note YP).\nNote YP: Rules for Posttherapy Pathological TNM Classification\nClassification of T, N, and M after systemic or radiation neoadjuvant treatment followed by surgery is denoted by\nuse of a lowercase yp prefix: ypT, ypN, c/pM. The c/pM category may include cM0, cM1, or pM1. The\nposttherapy pathological assessment of the T and N (ypTNM) categories uses specific criteria. In contrast, the M\ncategory for post neoadjuvant therapy classification remains the same as that assigned in the clinical stage\nbefore initiation of neoadjuvant therapy (e.g., if there is a complete clinical response to therapy in a patient\npreviously categorized as cM1, the M1 category is used for final yc and yp staging).\nThe time frame for assignment of ypT and ypN should be such that the post neoadjuvant therapy surgery and\nstaging occur within a period that accommodates disease-specific circumstances.\nCriteria: First therapy is systemic and/or radiation therapy followed by surgery.\ny-pathological (yp) classification is based on the:\n\u2022 y-clinical stage information, and supplemented/modified by\n\u2022 operative findings, and\n\u2022 pathological evaluation of the resected specimen.\nExamples of treatments that satisfy the definition of neoadjuvant therapy may be found in sources such as the\nNCCN Guidelines, ASCO guidelines, or other treatment guidelines. Systemic therapy includes chemotherapy,\nhormone therapy, and immunotherapy. Not all medications given to a patient meet the criteria for neoadjuvant\ntherapy (e.g., a short course of therapy that is provided for variable and often unconventional reasons, should not\nbe categorized as neoadjuvant therapy).\nSee Stage Classifications Table in Supplemental Information for additional guidance.\nPosttherapy Pathological Classification\nAfter initial primary systemic and/or radiation therapy, the patient may be operable and undergo a surgical\nresection with node dissection. The stage classification assigned is posttherapy pathological (ypTNM) and\nconsists of the ycTNM information obtained from physical examination, imaging, and biopsies, combined with the\nsurgeon's operative findings, and the information supplied from the pathologist on the resected specimen\npathology report. The ypT and ypN utilizes all of this information. The M category is the same as that assigned\n(cM0, cM1, or pM1) in the clinical stage.\nPosttherapy Pathological Classification of the T Category After Neoadjuvant Therapy\nFollowing neoadjuvant systemic therapy and surgical resection, posttherapy pathological assessment of the T\ncategory can be challenging due to difficulties assessing the size and extent of invasion (if any) of residual tumor.\nKey considerations for assigning the T category after neoadjuvant therapy and surgical resection are detailed\nbelow.\nIf the residual tumor is a discrete measurable mass, tumor size can be measured with a ruler. If the residual\ntumor is not a discrete measurable mass (e.g., multiple separate islands of viable tumor remain), tumor size can\nbe estimated by multiplying the percentage of viable tumor by the maximum dimension of the tumor bed.\nFor tumors that previously invaded structures, such as the chest wall or pericardium, the ypT category should be\nassigned based on the extent of invasion of the viable tumor in the resected specimen. For example, if a patient\nhas pre-treatment chest wall invasion (and is classified as T3) but no viable tumor is identified in the chest wall in\n29", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841686", "page": 31, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 3814}}
{"chunk_id": "tnm_lung_chunk_79", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n32/60", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841689", "page": 32, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 169}}
{"chunk_id": "tnm_lung_chunk_80", "text": "11/8/25, 11:55 AM\n\nthe resected specimen, the ypT category would be assigned based only on the size and extent of invasion of the\nremaining viable tumor.\nPosttherapy Pathological Classification of the N Category After Neoadjuvant Therapy\nFollowing neoadjuvant systemic therapy, patients undergoing surgical resection should receive adequate\nintraoperative nodal evaluation. Posttherapy pathological classification of the N category should be determined\nbased on the final pathology report.\nPosttherapy Pathological Classification of the M Category After Neoadjuvant Therapy\nIn contrast to the ypT and ypN categories, which are reassessed based on findings from the resected specimen\nand final pathology report, the M category is the same as that assigned (cM0, cM1, or pM1) in the clinical stage,\nregardless of the patient's response to therapy. For example, a patient with a tumor categorized as cM1 before\ntherapy will be categorized as cM1 for the final yp staging even if it had a complete clinical response to therapy.\nKey Considerations for Assigning Posttherapy Pathological T, N, and M Status\nNotably, data regarding the prognostic significance of T, N, and M status after neoadjuvant therapy and surgery\nare preliminary. Exploratory analyses have shown that survival of patients after neoadjuvant therapy, stratified by\npathological stage, is generally lower when compared to the survival of patients with a comparable pathological\nstage who do not receive neoadjuvant therapy (e.g., patients with pathological stage IIB lung cancer after\nneoadjuvant therapy had worse survival when compared to patients with pathological stage IIB lung cancer who\ndid not receive neoadjuvant therapy).  Importantly, however, given the preliminary nature of these data, in the\nVersion 9 TNM, there are currently no specific pathological stages for tumors that have undergone neoadjuvant\ntherapy (i.e., ypT, ypN, and cM/pM are not included in the stage group table shown in AJCC Prognostic Stage\nGroups). Therefore, once the ypT, ypN and cM/pM categories have been determined, the stage is to be assigned\naccording to the regular stage groups (as shown in AJCC Prognostic Stage Groups). For example, a patient with\na ypT1b ypN0 cM0 tumor would be classified as stage IA2.\nOf note, some patients with tumors assigned ypT0 have lymph nodes with residual viable tumor; for these\npatients, staging is stage IIA if the patient has ypT0 ypN1 cM0, stage IIB if the patient has ypT0 ypN2a cM0,\nstage IIIA if the patient has ypT0 ypN2b cM0, and stage IIIB if ypT0 ypN3 cM0.\nNote R: Rules for Recurrence/Retreatment TNM Classification\nStaging classifications at the time of retreatment for a recurrence or disease progression is referred to as\nrecurrence classification. It also may be referred to as retreatment classification. Classification of T, N, and M for\nrecurrence or retreatment is denoted by use of the lowercase r prefix: rcT, rcN, rc/rpM, and rpT, rpN, rc/rpM. The\nrc/rpM may include rcM0, rcM1, or rpM1.\nSee Stage Classifications Table in Supplemental Information for additional guidance.\nNote A: Rules for Autopsy TNM Classification\nStaging classification for cancers identified only at autopsy is referred to as autopsy classification. This\nclassification is used when cancer is diagnosed at autopsy and there was no prior suspicion or evidence of\ncancer before death. All clinical and pathological information obtained at the time of death and through post-\nmortem examination is included. Classification of T, N, and M at autopsy is denoted by use of the lowercase a\nprefix: aT, aN, aM.\nSee Stage Classifications Table in Supplemental Information for additional guidance.\nNote T: Primary Tumor (T)\nThe anatomy of the lung is described in Note S: Identification of Primary Site(s) with a figure of the anatomy. The\nfollowing figures depict the local extent of tumor described in the T categories.\n9", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841691", "page": 32, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 3898}}
{"chunk_id": "tnm_lung_chunk_81", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n33/60", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841694", "page": 33, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 169}}
{"chunk_id": "tnm_lung_chunk_82", "text": "11/8/25, 11:55 AM\n\nThe T category is assigned based on several factors, including the invasive size of the primary tumor, extent of\ninvasion, and number and location of tumor nodules (if there are multiple related tumor nodules). There are 11\ndifferent T categories, including TX, T0, Tis, T1mi, T1a, T1b, T1c, T2a, T2b, T3, and T4. Detailed descriptions of\neach of the T categories are provided below and are shown in the T Category Table in the Assignment of AJCC\nTNM section.\nClinical assessment of the primary tumor (cT) is usually based on evaluation of the primary tumor on a CT scan.\nThe pathological assessment of the primary tumor (pT) entails resection of the primary tumor or a biopsy\nspecimen adequate to evaluate the highest T and highest N categories.\nKey Considerations in Assigning T Categories\nA source of confusion in assigning T categories is whether to determine size based on the greatest dimension of\nthe tumor or the greatest dimension of the invasive component only. All AJCC definitions define T categories\nbased on the size of the invasive component.\nAnother source of confusion is the assignment of Tis versus T1mi. Tis is carcinoma in situ and includes\nsquamous cell carcinoma in situ and adenocarcinoma in situ (Figure Lung-Tis Adenocarcinoma In Situ).\nSquamous cell carcinoma in situ is defined as superficial tumor cells without any involvement of the basement\nmembrane. Adenocarcinoma in situ is defined as adenocarcinoma with a pure lepidic pattern that is \u2264 3 cm in\ngreatest dimension. In contrast, T1mi is minimally invasive adenocarcinoma (Figure Lung-T1mi Minimally\nInvasive Adenocarcinoma), which is defined as adenocarcinoma \u2264 3 cm in greatest dimension with a\npredominantly lepidic pattern and with an invasive component > 0 and \u2264 5 mm in greatest dimension. Pure\nground glass nodules or lepidic predominant nodules > 3 cm are defined as lepidic predominant\nadenocarcinomas (LPA) and are classified as T1a.\nFigure Lung-Tis Adenocarcinoma in Situ. A) CT shows a 2.0 cm pure ground glass nodule (white arrows). B)\nHistologically the tumor consists of a pure lepidic pattern of adenocarcinoma without any invasion (black arrows).\nC) Higher power shows crowded atypical pneumocytes lining slightly thickened alveolar walls (black arrows). No\ninvasive component is identified.\nFigure Lung-T1mi Minimally Invasive Adenocarcinoma. A) CT shows a 1.5 cm part solid nodule (white arrow)\nwith a predominant ground glass pattern surrounding a 0.5 cm solid component. B) Histologically a predominant\nlepidic component (black thick arrows) surrounds a 0.5 cm fibrotic scar with a focal area of invasive growth (black\nthin arrows). C) The lepidic component consists of slightly thickened alveolar walls lined by atypical pneumocytes\n(black arrows). D) This 0.2 cm focus of invasive adenocarcinoma shows glands, and solid nests infiltrate the fibrous\nstroma at one edge of the scar (black arrows).\nAdditionally, tumors less than 3 cm in greatest dimension with one or more of the following features should be\nclassified as T2a rather than T1a-c: 1) invades the visceral pleura, 2) invades an adjacent lobe, 3) involves the\nmain bronchus (up to but not including the carina), or associated with atelectasis, or obstructive pneumonitis,\nextending to the hilar regions involving either part of or the entire lung. Tumors less than 3 cm in greatest\ndimension without any of these features are classified as T1a-c (Figure Lung-T1a, T1b, T1c). However, tumors\nthat are less than 3 cm and have one or more of those features are classified as T2a.\nT2a also has a size criteria of > 3 cm but \u2264 4 cm, and T2b has a size criteria of > 4 cm but \u2264 5 cm (Figure Lung-\nT2a, T2b).\nIt should be noted that tumors that involve the following mediastinal structures are classified as T3 (Figure Lung-\nT3): pericardium, phrenic nerve, and azygos vein.\n29", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841696", "page": 33, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 3859}}
{"chunk_id": "tnm_lung_chunk_83", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n34/60\n\nIn classifying tumors as T4, it should be noted that tumors that involve the mediastinum (with the exception of the\npericardium, phrenic nerve, and azygous vein, which are classified as T3) are classified as T4 (Figure Lung-T4).\nTumors that involve the fatty tissue of the mediastinum are also classified as T4.\nFigure Lung-T1a, T1b, T1c.\nFigure Lung-T2a, T2b.\nFigure Lung-T3.\nFigure Lung-T4.\nVisceral pleural invasion is defined as invasion beyond the elastic layer or to the surface of the visceral pleura. A\ntumor that falls short of completely traversing the elastic layer is defined as PL0. A tumor that extends through\nthe elastic layer is defined as PL1, and one that extends to the surface of the visceral pleura as PL2. Elastic\nstains should be performed in cases in which there is any uncertainty based on review of hematoxylin and eosin\nsections. Either PL1 or PL2 status allows classification of the primary tumor as T2a. Extension of the tumor\nbeyond the visceral pleural surface to the parietal pleura of the chest wall or pericardium is defined as PL3,\ncategorizes the primary tumor as T3. Spread through the visceral pleural to the diaphragm muscle is PL3, but\ninvolvement of the diaphragm should be classified as pT4. Direct tumor invasion into an adjacent ipsilateral lobe\n(i.e., invasion across a fissure) or invading into hilar soft tissues is categorized as PL2 and classified as T2a,\nunless tumor size indicates a higher T category. Figure Lung-Visceral Pleura Invasion shows the graphic\nrepresentation of visceral and parietal pleura invasion.\nFigure Lung-Visceral Pleura Invasion. See text for definitions.\nSince the 7  Edition TNM stage classification, WHO has defined new entities of adenocarcinoma in situ and\nminimally invasive adenocarcinoma. It also has histologically classified non-mucinous adenocarcinomas based\non an estimate of percentages of lepidic and invasive (acinar, papillary, solid, and micropapillary) patterns. In\ngeneral, the lepidic-versus-invasive patterns by histology correspond to ground-glass versus solid components\nby CT.\nTis includes adenocarcinoma in situ (AIS) and squamous cell carcinoma in situ (SCIS). Because the histologic\ntype of in situ carcinoma does not always match that of the associated primary lung carcinoma, it is important to\nspecify Tis (AIS) versus Tis (SCIS).\n30\nth", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841699", "page": 34, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 2510}}
{"chunk_id": "tnm_lung_chunk_84", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n35/60", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841701", "page": 35, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 169}}
{"chunk_id": "tnm_lung_chunk_85", "text": "11/8/25, 11:55 AM\n\nAIS is a localized small (less than or equal to 3 cm) adenocarcinoma with growth restricted to neoplastic cells\nalong pre-existing alveolar structures (lepidic growth) and lacking stromal, vascular, alveolar space, or pleural\ninvasion. Most AISs are non-mucinous, but rarely, they may be mucinous. Most AISs show a pure ground-glass\nnodule by CT, unless there are benign areas such as fibrous scar, inflammation, or organizing pneumonia\ncontributing to a solid component.\nMinimally invasive adenocarcinoma (MIA) is defined as a lepidic-predominant adenocarcinoma measuring up to\n3 cm with an invasive component measuring up to 0.5 cm. Most MIAs are non-mucinous, but rarely, they may be\nmucinous. In some non-mucinous MIA cases, there is a single, discrete focus of invasion or a solid component\non CT. However, if the invasive/solid component assessed by histology/CT, respectively, consists of multiple foci,\nit is proposed that the percentage area of the invasive/solid be estimated and then multiplied by the total size.\nFor example, a 2.0 cm total size with a 20% invasive or solid component on histology or CT, respectively, would\nhave an estimated size of 0.4 cm.\nTo measure tumor size in part-solid, non-mucinous adenocarcinomas, the recommendation is to follow the TNM\nrule to consider only the size of the invasive component in assigning a T category. This recommendation does\nnot apply to other histologic types of lung cancer or to mucinous lung adenocarcinomas. Although this general\nrule has been in place since 2001, until now it has not been applied in lung adenocarcinoma.\nTherefore, a\nlesion consisting of a 15 mm part-solid opacity with a 7 mm solid component would be classified as a cT1a\nlesion, because its solid component, excluding the ground-glass component, is less than 10 mm in greatest\ndimension. If the lesion is resected and proves to be an adenocarcinoma with lepidic and invasive components,\nthe measurement of the invasive component at pathological examination will be used for the pathological\nclassification. This recommendation is based on the increasing number of studies in small lung adenocarcinomas\nreporting that in part-solid adenocarcinomas, it is the invasive component that correlates with prognosis.\nSimilar to MIA, in cases in which multiple invasive/solid areas, rather than a single, discrete focus, are observed\non histology/CT, it is proposed that the percentage invasive/solid area be multiplied by the total tumor size to\nestimate the size of invasion.\nIt is recommended that both total size and invasive/solid size continue to be\ndocumented in radiology and pathology reports.\nIn special situations, tumor size is determined after induction therapy. If no viable tumor cells remain after\ninduction therapy, the tumor is classified as ypT0. However, no rules have been established to measure tumor\nsize in patients who have had a partial response, the degree of which has prognostic relevance. A practical way\nto estimate tumor size is to multiply the percentage of viable tumor cells by the size of the total mass. This\nformula may be applied in cases in which there are multiple foci of viable cells or the viable tumor is on multiple\nblocks.\nIf the viable tumor is a single focus measurable on gross exam or on a single microscopic slide, size\ncan be determined with a ruler.\nNote N: Regional Lymph Nodes\nSpread to the regional lymph nodes is a common feature in lung cancer. The assignment of N status is based on\nthe presence of disease in lymph node stations (Figure Lung-Nodal Map) (Table Lung-Anatomic Definitions of\nLymph Node Stations). There are 7 different N categories, including NX, N0, N1, N2, N2a, N2b, and N3. Detailed\ndescriptions of each of the N categories are provided below and are shown in the N Category Table in the\nAssignment of AJCC TNM section.\nKey Considerations in Assigning N Categories\nThe assignment of N categories is based on the presence of tumor in lymph nodes in a given lymph node\nstation. The assignment of N categories is not based on the total number of lymph nodes that have tumor. For\nexample, a patient may have disease in multiple lymph nodes from a single nodal station; only the nodal station\ninvolved would be included in the determination of the N category.\nThe N1 category is illustrated below (Figure Lung-N0, N1). There are also illustrations for N2 (Figure Lung-N2a;\nN2b).\n31, 32\n29, 31, 32\n10, 29\n33-35\n29\n36\n29", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841704", "page": 35, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 4441}}
{"chunk_id": "tnm_lung_chunk_86", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n36/60\n\nThe presence of micrometastic disease (metastases no larger than 0.2 cm) identified in a regional lymph node is\nclassified as N1(mi), N2(mi) or N3(mi). While this is not included in the Definition of Regional Lymph Nodes (N), it\nis recommended for prospective registration in data. The presence of disease in ipsilateral or contralateral\nsupraclavicular and lower cervical (caudal to the inferior border of the cricoid cartilage) nodes is classified as N3\n(Figure Lung-N3).\nThe natural progression from the primary tumor to the intrapulmonary, hilar, mediastinal, and supraclavicular\nlymph nodes is not found in every patient with lung cancer and nodal disease. Some patients have mediastinal\nnodal disease without intrapulmonary or hilar nodal involvement, which are referred to as skip metastases. Table\nLung-Anatomic Definitions of Lymph Node Stations shows the regional pulmonary, mediastinal, and\nsupraclavicular lymph nodes. It also describes the anatomic limits of the nodal stations and their grouping in\nnodal zones.\nThe medial border for nodal stations 3a and 3p is not defined in the regional lymph node map or in the table of\nthe anatomic definitions of the different nodal stations. For the purpose of staging, the anatomic midline of the\ntrachea distinguishes N2 from N3 nodes in these nodal stations.\nThe pathological assessment of the regional lymph nodes (pN) entails removal of enough nodes to validate the\nabsence of regional lymph node metastasis (pN0) or to evaluate the highest pN category.\nFigure Lung-Nodal Map. International Association for the Study of Lung Cancer lymph node map.\nTable Lung-Anatomic Definitions of Lymph Node Stations. Anatomic definitions for each lymph node station\nand station grouping by nodal zones in the map proposed by the IASLC.\nFigure Lung-N0, N1.\nFigure Lung-N2a.\nFigure Lung-N2b.\nFigure Lung-N3.\n37", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841706", "page": 36, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 2023}}
{"chunk_id": "tnm_lung_chunk_87", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n37/60", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841708", "page": 37, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 169}}
{"chunk_id": "tnm_lung_chunk_88", "text": "11/8/25, 11:55 AM\n\nLymph Node Assessment\nFor proper pathological lymph node staging and to fulfill the requirements for complete resection and\npathological N0, the IASLC recommends performing a systematic nodal dissection. Systematic nodal dissection\nis the en bloc removal of the mediastinal fatty tissue, including the lymph nodes, which should be followed by\nhilar and intrapulmonary nodal dissection.\nLobe-specific systematic nodal dissection consists of the removal of\ncertain mediastinal lymph nodes, depending on the lobar location of the primary tumor.\nThe mediastinal nodal\nstations that should be removed, according to the location of the primary tumor, are as follows (based on the\nIASLC lymph node map in Figure Lung-Nodal Map):\n\u2022 Right upper and middle lobes: 7, 2R, and 4R\n\u2022 Right lower lobe: 7, 4R, and 8 or 9\n\u2022 Left upper lobe: 7, 5, and 6\n\u2022 Left lower lobe: 7, 8, and 9\nIn any case, at least six lymph nodes/stations (six lymph nodes from six lymph node stations) should be\nremoved.\nThree of these nodes/stations should be mediastinal, including the subcarinal nodes (nodal station\n#7), and three should be hilar-intrapulmonary lymph nodes/stations. The AJCC and the Union for International\nCancer Control (UICC) accept that if all resected/sampled lymph nodes are negative, but the number\nrecommended is not met, the classification is pN0. If resection has been performed, and otherwise fulfills the\nrequirement for complete resection, the classification is R0.\nHowever, the ACCP recommends the\nclassification of pN0(un), un for uncertain, if the number of recommended lymph nodes removed /sampled is not\nmet. The suffix (un) also should be added to pN1, and pN2 if fewer than six lymph nodes are evaluated.\nThis\nsuffix is not added to the N categories, as it is an opinion of the ACCP that has not been discussed sufficiently at\nthe international level or approved by the AJCC or UICC. Nevertheless, it makes sense to use it in cases in\nwhich the required standards of intraoperative lymph node examination are not met, especially when it has been\nproven that failure to perform a proper lymphadenectomy has had deleterious prognostic implications.\nOther standards for nodal dissection have been released, including the American College of Surgeons (ACS)\nCommission on Cancer (CoC) Optimal Resources for Cancer Care Standard 5.8. This is also in the ACS\nOperative Standards for Cancer Surgery, Volume 1. Previously, the ACS CoC quality metric for lymph node\nassessment required the sampling or dissection of at least 10 lymph nodes from any nodal station in the chest.\nHowever, in 2020, the ACS Cancer Surgery Standard Program updated their quality metric for lymph node\nassessment (CoC Standard 5.8). The CoC Standard 5.8 requires nodal sampling of at least three distinct\nmediastinal nodal stations and at least one hilar nodal station.\nOf note, current standards for lymph node assessment allow for either lymph node dissection or sampling, based\non the findings of ACS Oncology Group Z0030.\nACS Oncology Group Z0030 reported that systemic lymph\nnode sampling had equivalent overall survival when compared to complete lymphadenectomy among patients\nwith T1-T2 N0-N1 (non-hilar) disease. These findings support that systemic lymph node sampling is appropriate\namong patients with stage I-II lung cancer. However, among patients with stage IIIA-N2 lung cancer, a complete\nlymph node dissection is recommended.\nNote M: Metastatic Sites\nThe M category is assigned based on the method of assessment, not the classification. The options are cM0,\ncM1, and pM1. cM0 indicates no distant metastasis by signs/symptoms, imaging, etc.; no evidence of tumor in\ndistant sites or organs. This category is not assigned by pathologists. cM1 indicates the distant metastasis are\nidentified through physical exam, signs or symptoms, any imaging results, or direct visualization during\nprocedures. pM1 indicates at least one site of distant metastasis has been confirmed microscopically; such\nmicroscopic evidence includes tumor identified in biopsy, resection, or cytology from fine needle aspiration. Not\nall sites of distant metastasis must be confirmed microscopically in order to assign pM1.\n38\n39\n40\n10, 18\n39\n41\n42", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841711", "page": 37, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 4225}}
{"chunk_id": "tnm_lung_chunk_89", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n38/60\n\nKey Considerations in Assigning M Categories\nThe terms pM0, cMX and pMX are not valid categories. Although any organ may be the site of metastasis from\nprimary lung cancer, the brain, bones, adrenal glands, contralateral lung, liver, pericardium, kidneys, and\nsubcutaneous tissue are the most common sites of metastatic spread. In the absence of specific clinical findings,\nthe staging process should focus on ruling out metastasis in these common sites. The pathological assessment\nof distant metastasis (pM) entails microscopic examination. For pathological staging, cM0 or cM1 categories also\nare valid.\nIn assigning the M1a category (Figure Lung-M1a), tumor with separate (i.e., not continuous with the primary\ntumor) pleural or pericardial nodules is classified as M1a. Additionally, microscopic disease that is discontinuous\nfrom the primary tumor in the ipsilateral parietal or visceral pleura is classified as M1a. Tumor nodules in the\ncontralateral lung and malignant pleural or pericardial effusions also are criteria to assign the M1a category.\nIn assigning M1b category (Figure Lung-M1b), a single extrathoracic metastasis in a single organ system is\nclassified as M1b. Involvement of a single non-regional node would also be classified as M1b.\nIn assigning M1c1 (Figure Lung-M1c1) (multiple extrathoracic metastases to a single organ system) versus M1c2\n(Figure Lung-M1c2) (multiple extrathoracic metastases to multiple organ systems) categories, paired organs,\nsuch as the kidneys and adrenal glands, are considered to be single organ systems. Bilateral extrathoracic\nmetastases limited to a single organ system (e.g., metastases in the left and right adrenal glands) are classified\nas M1c1, and not M1c2. Additionally, metastases to multiple extrathoracic lymph nodes are classified as M1c1, if\nthere are no metastases in other extrathoracic organ systems.\nFigure Lung-M1a.\nFigure Lung-M1b.\nFigure Lung-Mlc1.\nFigure Lung-M1c2.\nNote PFR: Prognostic Factors Required for Stage Grouping\nBeyond the factors used to assign T, N, or M categories, no additional prognostic factors are required for stage\ngrouping.\nNote PSG: AJCC Prognostic Stage Groups", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841713", "page": 38, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 2329}}
{"chunk_id": "tnm_lung_chunk_90", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n39/60", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841716", "page": 39, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 169}}
{"chunk_id": "tnm_lung_chunk_91", "text": "11/8/25, 11:55 AM\n\nThe managing physician alone is responsible for assigning the patient's stage, because only (s)he routinely has\naccess to all the pertinent information from physical examination, imaging studies, biopsies, diagnostic\nprocedures, surgical findings, and pathology reports. Although the pathologist and the radiologist provide\nimportant staging information, and may provide important T-, N-, and/or M-related information, stage is defined\nultimately from the synthesis of an array of patient history and physical examination findings supplemented by\nimaging and pathology data.\nTumor stage is a function of the T, N, and M components of the classification, and changes in their categories\nmay influence tumor stage. In Version 9 of the classification, there are changes in the N and M categories. The\nN2 category is subdivided into N2a (involvement of a single N2 nodal station) and N2b (involvement of multiple\nN2 nodal stations). This change was based on differences in overall survival that were found both at clinical and\npathological classification.  This subdivision originated new tumor groups that were assigned to different stages\naccording to the survival associated with them based on the analyses of the database used to inform Version 9.\nThe changes in Version 9 in comparison with the 8  edition are :\n\u2022 T1 N2a M0 tumors have better survival than tumors in stage IIIA and similar survival to that of those in stage\nIIB; therefore, they were assigned to stage IIB.\n\u2022 T1 N1 M0 tumors have better survival than tumors in stage IIB and similar survival to those in stage IIA;\ntherefore, they were assigned to stage IIA.\n\u2022 T2 N2b M0 tumors have worse survival than tumors in stage IIIA and similar survival to that of those in stage\nIIIB; therefore, they were assigned to stage IIIB.\n\u2022 T3 N2a M0 tumors have better survival than tumors in stage IIIB and similar survival to that of those in stage\nIIIA; therefore, they were assigned to stage IIIA.\nThe subdivision of M1c into M1c1 (multiple extrathoracic metastases in a single organ system) and M1c2\n(multiple extrathoracic metastases in multiple organ systems) does not alter stage IVB because both are\nassigned to this stage.\nIt is important to note that Version 9 clinical stages IIIC and IVA have similar prognosis, a finding also observed in\nthe 8  edition. However, the decision was to keep these tumors separated because they represent different\nforms of anatomic tumor extent: IIIC represents locally advanced tumors and IVA distant intrathoracic metastases\nor single extrathoracic metastasis. Therefore, it makes sense to keep them in separate stages despite their\nsimilar prognosis.\nSurvival Data\nThe 3  phase of the IASLC's International Lung Cancer Staging Project included 73,197 eligible NSCLC cases\nfor analysis of the different TNM categories. Eligible cases met pre-specified quality checks and were diagnosed\nbetween January 2011 and December 2019, with survival updates up to December 2021. They included 65,060\nclinically staged and 47,513 pathologically staged tumors.  The number of cases used for each of the TNM\ncategories varied, depending on the availability of required details.\nSurvival Implications of the T-Categories\nThe analyses of the Version 9 IASLC database concerning the primary tumor (T) category of the TNM\nclassification corroborated the changes made in the 8  edition, confirming the greater prognostic relevance of\ntumor size than had been acknowledged in earlier editions. Each centimeter increase in size, from less than 1\ncm to up to 5 cm, separates tumors of significantly different prognosis, and tumors > 7 cm have prognosis similar\nto tumors invading critical mediastinal structures (T4). Furthermore, although prognosis worsens with more\ncentral tumor invasion, endobronchial tumors not involving the carina (irrespective of proximity to within 2 cm of\nthe carina), and those causing complete atelectasis or pneumonitis, do not have a worse prognosis than those\nmore than 2 cm from the carina or those causing partial atelectasis and pneumonitis. Figure Lung-Survival\n7\n5\nth\n9\n8\nth\n9\nrd\n5\nth", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841718", "page": 39, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 4119}}
{"chunk_id": "tnm_lung_chunk_92", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n40/60", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841721", "page": 40, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 169}}
{"chunk_id": "tnm_lung_chunk_93", "text": "11/8/25, 11:55 AM\n\nAccording to T Category  shows the survival plots of the 8  edition T categories for clinically (A) and\npathologically (B) staged tumors with no nodal involvement and no metastases, in the Version 9 dataset. The\npairwise comparisons show significant differences between adjacent T-categories, with the sole exception of the\ncomparison between clinical T2b and T3.\nFigure Lung-Survival According to T Category. (A and B) Survival curves for the different T categories to\nvalidate the eighth edition criteria for M0, N0, and any R cases (clinical staging, left panel; pathological staging,\nright panel).\nThe Version 9 dataset analysis tested the hypothesis that patients with chest wall and parietal pleural (PL3)\ninvasive tumors have a worse prognosis than patients with T3 tumors defined by other descriptors (size > 5 cm\nto 7 cm, satellite metastasis in the same lobe as the primary tumor, invasion of the azygos vein, phrenic nerve,\npericardium or thoracic nerve root). In the pathologically staged cohort, survival was significantly worse in the\nchest wall/PL3 invasion cohort, with 5-year overall survival (OS) of 53% versus 60% when any N was included\nand 55% versus 68% when restricted to pN0 (p<0.0001 for both comparisons). However, in the clinically staged\ncohort, there was no significant difference with 5-year survival rates of 47% versus 51% (p= 0.0721) when any\ncN was included and 47% versus 56% (p = 0.8093) when restricted to cN0. The discordant findings resulted in\nconsensus to leave the 8  edition T-categories unchanged in Version 9.\nSurvival Implications of the N-Categories\nAlthough the analyses performed using the Version 9 IASLC database validated the clinical and pathological\nstaging descriptors used from the 4  to the 8  edition,  it also became evident that further sub-classification of\nthe N2 category according to the number of ipsilateral mediastinal or subcarinal lymph node stations involved\nwith metastasis clearly demarcated two subsets of N2. Patients with metastasis to a single ipsilateral mediastinal\nlymph node station or the subcarinal station (N2a) had significantly better survival than those with metastasis to\ntwo or more such lymph node stations (N2b). The difference was clinically and statistically significant in clinically\nand pathologically staged tumors (Figure Lung-Survival cN and pN Category Comparisons). There remained a\nclear and consistent survival demarcation between the adjacent clinical and pathological N subsets - N0 versus\nN1, N1 versus N2a, N2a versus N2b, N2b versus N3 (Table Lung-Pair-Wise Comparisons of Survival According\nto N Category). Furthermore, the difference between N2a and N2b was consistent and robust across multiple\nsensitivity analyses, including histologic type (Figure Lung-Survival According to N Category\nSquamous/Nonsquamous), T-categories (Figure Lung-Survival N Category Stratified According to T Categories),\nand geographic region. The separation was consistent even in neoadjuvant treated cohorts (Figure Lung-\nSurvival ypN Category Comparison 8  Versus Version 9). Finally, the results were reproducible in analysis of the\n8  edition dataset (Figure Lung-Survival pN Category Comparisons Using the 8  Edition Dataset).\nThese analyses confirmed the long-held belief in the prognostic impact of the burden of mediastinal lymph node\ndisease. Although this burden might be quantified in other ways, including the counting of lymph nodes or\napplication of the previously recommended lymph node zone concept,\nthe number of ipsilateral mediastinal\nlymph node stations with metastasis was selected because of its relative simplicity, feasibility with contemporary\nradiologic, invasive clinical staging and pathological staging modalities, and the need to avoid confounding by the\nenumeration of fragmented lymph nodes. It also has the advantage of backward compatibility with the previous\nN-categories and relative ease of comprehension and application, compared to the lymph node zone concept.\nThe new distinction between N2a and N2b aligns relatively well with current clinical practice and is likely to spur\non studies exploring the responsiveness of subsets of patients with mediastinal lymph node metastasis to\nspecific treatment modalities such as surgical resection and emerging neoadjuvant and adjuvant therapies.\nAlready, in 2024, a number of emerging neoadjuvant and adjuvant therapy clinical trials have proposed using the\nN2a subset as a defining point in their eligibility criteria.\n6\nth\n6\nth\nth\nth\n7\nth\nth\nth\n37\n43", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841723", "page": 40, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 4540}}
{"chunk_id": "tnm_lung_chunk_94", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n41/60", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841726", "page": 41, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 169}}
{"chunk_id": "tnm_lung_chunk_95", "text": "11/8/25, 11:55 AM\n\nFigure Lung-Survival cN and pN Category Comparisons. Comparison of current (eighth edition) to proposed\nVersion 9 N categories; (A1-2) overall survival by cN categories, and (B1-2) pN categories. cN, clinical node; pN,\npathological node.\nTable Lung-Pair-Wise Comparisons of Survival According to N Category. Adjusted HRs comparing overall\nsurvival between proposed Version 9 N categories, on the basis of the Cox Proportional Hazards Model with\ncovariates of proposed Version 9 N category, sex, age, histologic type, history of previous malignancy, geographic\nregion, and completeness of resection (for pathologically staged tumors).\nFigure Lung-Survival According to N Category Squamous/Nonsquamous. Validation analyses comparing the\neighth edition to proposed Version 9 N categories with respect to histologic type; overall survival by clinical N\ncategories (A) squamous, and (B) non-squamous. N, node.\nFigure Lung-Survival N Category Stratified According to T Categories. Validation analysis of the proposed\nVersion 9 N categories stratified according to T categories (A-D); overall survival by clinical N categories.\nFigure Lung-Survival ypN Category Comparison 8th Versus Version 9. Validation analysis comparing eight\nedition to proposed Version 9 N categories in postneoadjuvant therapy patients (ypN); overall survival by\npathological N categories. ypN, post-treatment pathological node.\nFigure Lung-Survival pN Category Comparisons Using the 8th Edition Dataset. Validation analysis comparing\nthe eighth edition to the proposed Version 9 N categories using the previous eighth edition data set; overall survival\nby pN categories. pN, pathological node.\nSurvival Implications of the M-Categories\nThe IASLC database included 14,937 patients with M1 NSCLC with sufficient details with which to validate the\nM1a (malignant pleural or pericardial effusion or nodules, contralateral lung metastasis), M1b (single metastatic\nlesion in a single extrathoracic site, including non-regional lymph nodes), and M1c (multiple sites of metastasis in\na single organ system or multiple organ systems) categories established with the 8  edition. The dataset\nconsisted of information from 2839 patients entered directly into an Electronic Data Capture (EDC) system, 780\npatients from SWOG 0819 trial also entered into the EDC, and 11,318 patients whose data were submitted\noutside the EDC and had to be mapped to the EDC.  The 3619-patient data submitted through the EDC had\nmore complete details about the number of lesions in organ systems involved with metastasis, permitting\nadditional analyses not possible with the non-EDC dataset.\nThe M-categories of the 8  edition were validated in the Version 9 dataset, including the similarity between the\nM1a and M1b categories and the significant survival degradation in the cohorts with multiple sites of metastasis\n(Figure Lung-Survival According to M Category). In addition, the details available in the larger Version 9 dataset\npermitted examination of the prognostic impact of the number of extrathoracic organ systems involved with\nmetastasis. This revealed significant survival difference between cohorts with multiple sites of metastasis in one\nextrathoracic organ system (now delineated as M1c1) and cohorts with metastasis to multiple extrathoracic\norgan systems (now identified as M1c2).\n7\n7\n7\n7\n7\n7\nth\n8\nth", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841728", "page": 41, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 3376}}
{"chunk_id": "tnm_lung_chunk_96", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n42/60", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841731", "page": 42, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 169}}
{"chunk_id": "tnm_lung_chunk_97", "text": "11/8/25, 11:55 AM\n\nFigure Lung-Survival According to M Category. Analysis of metastatic lesions and organ systems involved.\nAlthough the prognosis of cohorts of patients with intrathoracic metastases (M1a) was similar to that of cohorts\nwith single extrathoracic metastasis (M1b), as in the 8  edition, they are coded separately for practical reasons,\nsince they represent different anatomic extents of disease and require different diagnostic and therapeutic\nstrategies. Furthermore, in a Cox regression analysis stratified by data source (EDC and non-EDC) and adjusting\nfor age, sex, histology, and geographic region, the M1b cohort had an adjusted hazard ratio of 1.18 (p< .001);\n(Table Lung-Multivariable Analysis of Survival According to M Category). Nevertheless, also consistent with the\n8  edition's approach, M1a and M1b remain combined in defining stage IVA. The two prognostically different\nsubsets of M1c (M1c1 and M1c2) also remain combined as stage IVB (Table Lung-Multivariable Analysis of\nSurvival of Stage IV According to the Number of Metastatic Lesions and Involved Organ Sites). Despite this\npragmatic approach, it is hoped that coding them separately will permit further data collection and stimulate\nfurther study of these subsets of M1 disease.\nIn exploratory analyses, the dataset was also used to examine the prognostic impact of cytologic confirmation of\nmalignant pleural effusion, the maximum size of the largest metastatic lesion, and the number of extrathoracic\nmetastatic lesions and organ sites with metastasis in an exploration of possible thresholds for defining oligo-\nmetastatic disease. Cytologic confirmation of malignant pleural effusion had survival impact neither among\npatients with a pleural effusion as the sole M1a descriptor nor patients with other M1a descriptors. For this\nreason, the AJCC/UICC recommendation for clinical judgment in determining when and how far to pursue\ncytological confirmation of malignant effusions was reiterated.\nIn a limited dataset of 552 patients with M1b or M1c and available size data, the median lesion size was 2.0 cm\n(range 0.1 to 19.2 cm) and the optimal cut-point for survival was 1.2 cm. Patients with a maximal lesion size\nbelow the cut-point had better survival than those with larger lesions (p = .02). The small sample size precluded\nfurther examination of this finding, which was recommended for further research. The size of the largest\nmetastatic lesion was therefore not recommended as an M category descriptor.\nAmong 1258 patients with reported number of metastatic lesions a cut-point analysis suggested seven lesions as\nthe optimal cut-point, but the limited number of cases precluded a training/validation analysis. Furthermore, the\nnumber of lesions seemed to be a continuum, without a clear inflection point and the analysis was probably\nconfounded by insufficient treatment details. The number of metastatic lesions was not recommended for\ninclusion as an M category descriptor. Similarly, comparison of survival among patients with M1c according to the\ninvolvement of 1, 2, 3 or \u2265 4 organ sites of metastasis, in comparison to M1b (single lesion at a single site)\nrevealed statistically significant differences between M1b and the M1c subgroup above or below the threshold\nnumber of involved organ sites. The number of involved organ sites (beyond two, to define M1c2) is not included\nas an M descriptor for Version 9.\nTable Lung-Multivariable Analysis of Survival According to M Category. Cox regression for overall survival by\nnumber of lesions and sites, stratified by data source; analysis of M categories.\nTable Lung-Multivariable Analysis of Survival of Stage IV According to the Number of Metastatic Lesions\nand Involved Organ Sites. Cox regression overall survival by number of lesions and sites, stratified by data\nsource; analysis of Stage IV groups.\n8\nth\nth\n8\n8\n8", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841733", "page": 42, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 3876}}
{"chunk_id": "tnm_lung_chunk_98", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n43/60\n\nSurvival Implications of the Reconfigured Aggregate TNM Stage Groupings\nThe identification in the Version 9 of prognostically different N2 subsets-N2a (metastasis to one ipsilateral\nmediastinal or subcarinal lymph node station) and N2b (metastasis to two or more ipsilateral mediastinal or the\nsubcarinal station)- doubled the number of possible T N2 M0 combinations from five to ten (T1 N2a M0, T1 N2b\nM0, T2a N2a M0, T2a N2b M0, T2b N2a M0, T2b N2b M0, T3 N2a M0, T3 N2b M0, T4 N2a M0, T4 N2b M0).\nThis change includes clinically and statistically significant differences in survival over the previously\nundifferentiated N2 combinations with the five different T categories from the 8  edition. For this reason, some of\nthe T N2 M0 combinations have been realigned to different stage groupings.  Probably the most important of\nthese changes is the re-categorization of T1 N2a M0 as stage IIB, rather than IIIA. This change seems drastic\nbecause it eliminates the previously simple rubric that mediastinal lymph node involvement established stage III\ndisease. Other changes include the 'demotion' of T1 N1 M0 from stage IIB to IIA, T3 N2a M0 from stage IIIB to\nIIIA, and the 'promotion' of T2 N2b M0 from IIIA to IIIB. (Figure Lung-Comparison of Aggregate TNM Stage\nGroupings)\nFigure Lung-Comparison of Aggregate TNM Stage Groupings. Comparison of 8  Edition and Version 9 stage\ngroupings.\nThese changes were necessitated by the profound survival difference between N2a and N2b. The reconfigured\naggregate clinical and pathological stages show clean, sequentially ordered separation between the survival\nplots of all aggregate stage groupings influenced by the N2a/N2b dichotomy (Figure Lung-Survival Clinical Stage\nComparison). Overall, the Version 9 aggregate stage groups show clean, clear, ordered, clinically and statistically\nsignificant separation between the different stage subsets, with the sole exception of stage IIIC/IVA. This pattern\nof similar survival between IIIC/IVA was also present in the 8  edition.\nAs before, the separate coding is\njustified by the different treatment approaches typically used in these cases. The separation between M1c1 and\nM1c2 has made no impact on aggregate staging, as they are both assigned as IVB, irrespective of T or N\ncategory.\nFigure Lung-Survival Clinical Stage Comparison. Comparison of 8  Edition and Version 9 survival.\nNote AF: Additional Factors Impacting Treatment Decisions During First Treatment\nPhase", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841736", "page": 43, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 2632}}
{"chunk_id": "tnm_lung_chunk_99", "text": "Prognostic Tumor Characteristics\n\nRadiographic Features\nRadiographic features of the primary tumor are associated with prognosis and may influence treatment\ndecisions. For instance, slowly growing nodules or non-solid nodules that develop a solid component slowly over\ntime are associated with less aggressive forms of adenocarcinoma.\nThis knowledge may influence decisions\nsuch as the extent of resection for a peripheral, < 2 cm nodule (e.g., sublobar versus lobar resection).\nThe\nmaximum standardized uptake value (SUV\n) of the tumor is also associated with survival,\nthough it is less\nclear how this knowledge may influence treatment decisions. It is possible that high SUV\nvalues along with\nother negative prognostic factors (see below) may influence decisions to recommend adjuvant systemic therapy\nwhen other clear indications for additional treatment (e.g., nodal disease) are not present. Even if radiographic\nfeatures do not influence treatment decisions, they may influence other aspects of management such as the\nintensity of post-treatment surveillance. AJCC Level of Evidence: I\nPathologic Features\nPathologic features of the tumor are associated with prognosis and may influence treatment. Histology influences\ndecisions about the type of systemic therapy administered. Pathologic features of the primary tumor associated\nth\n9\nth\n9\nth\n44\nth\n9\n45\n46\nmax\n47\nmax", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841738", "page": 44, "cancer_type": "Lung", "category": "Unknown", "section": "Prognostic Tumor Characteristics", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 1374}}
{"chunk_id": "tnm_lung_chunk_100", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n44/60", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841741", "page": 44, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 169}}
{"chunk_id": "tnm_lung_chunk_101", "text": "11/8/25, 11:55 AM\n\nwith worse outcomes include higher tumor grade, vascular invasion, lymphatic permeation, perineural invasion,\npleural invasion (PL1-3), and spread through air spaces (STAS). Some of these findings may influence decisions\nto recommend adjuvant systemic therapy when other clear indications for additional treatment (e.g., nodal\ndisease) are not present. STAS is associated with lower overall and recurrence-free survival and higher risks of\nlocal recurrence and distant recurrence. Recommended as a new histologic descriptor, STAS is defined as the\npresence of tumor cells within the first alveolar spaces in the lung parenchyma beyond the edge of the main\ntumor. To diagnose STAS, at least two clusters should be present, and it is important to exclude artifacts.\nSTAS may influence treatment decisions in several ways.\nSome recommend lobectomy when it is found on\nfrozen section. However, routine reporting of STAS on frozen section remains in the implementation phase and\nthe diagnosis is associated with both false-negative and false-positive classifications.\nGiven the association\nwith a higher risk of distant recurrence, its presence may influence treatment decisions.\nAnother critically important pathologic finding in surgically treated patients is residual tumor using the following\nclassification scheme (Table Lung-Residual Tumor After Surgical Resection).\nTable Lung-Residual Tumor After Surgical Resection.\nR1 or R2 resections influence decisions to recommend adjuvant therapy.\nEven if pathologic features do not\ninfluence treatment decisions, they may influence other aspects of management such as the intensity of post-\ntreatment surveillance. AJCC Level of Evidence: I\nGenetic and Molecular Features\nGenetic and molecular features are associated with prognosis and may influence treatment. Patients with the\nfollowing mutations have targeted therapies and better response compared to systemic chemotherapy:\nepidermal growth factor receptor (EGFR) (exon 19 deletions, p.L858R point mutation in exon 21);\nB-RAF\nproto-oncogene (BRAF); KRAS proto-oncogene (KRAS);\nmesenchymal-epithelial transition (MET) exon 14\n(METex14);\nErb-B2 receptor tyrosine kinase 2 (ERBB2)/HER2;\nand neurotrophic tyrosine receptor kinase\n(NTRK1/2/3). Additionally, patients with the following gene rearrangements have targeted therapies and a better\nresponse compared to systemic therapy alone: anaplastic lymphoma kinase (ALK) gene rearrangement;\nROS\nproto-oncogene 1 (ROS) gene rearrangement;\nand rearranged during transfection (RET) gene\nrearrangements.\nProgrammed death ligand 1 (PD-L1) is a co-regulatory molecule and levels of expression are\nassociated with response to immunotherapy.\nAJCC Level of Evidence: I\nNon-Tumor Factors\nPatient Demographics\nAge, sex, race, and ethnicity are associated with overall survival.\nAlthough increasing age is associated with\nworse outcome, age alone should not be a basis for denying patients treatment. Age may reasonably inform\ntreatment and care decisions in terms of its obvious implications for estimated life expectancy. Sex-based\nassociations with survival are not well understood biologically, though genomic, metabolic, and hormonal\nmechanisms have been considered.\nWomen have historically had better overall survival rates than men,\nalthough the difference is narrowing with improving survival for men over time.\nThere is no known biologic\nbasis for well documented associations between overall survival and race and ethnicity. Social determinants of\nhealth may explain a majority or all the observed differences in outcomes by sex, race, and ethnicity. In the\nabsence of a biological basis for the association between overall survival and sex, race, and ethnicity, these\ndemographic factors should not be the basis for treatment decisions. AJCC Level of Evidence: I\nMode of Presentation\n48-51\n48-51\n52\n40\n53, 54\n55-57\n58, 59\n60, 61\n62\n63\n64\n65\n66, 67\n68\n69\n68", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841744", "page": 44, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 3920}}
{"chunk_id": "tnm_lung_chunk_102", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n45/60", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841747", "page": 45, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 169}}
{"chunk_id": "tnm_lung_chunk_103", "text": "11/8/25, 11:55 AM\n\nThe mode of presentation \u2014 symptomatic, incidentally-detected, and screen-detected \u2014 is inferred to be\nassociated with outcome because of their association with stage at diagnosis. Two randomized trials\ndemonstrated that the frequency of early stage disease at diagnosis was higher for screen-detected individuals\ncompared to those who did not undergo screening.\nPatients with incidentally-detected lung cancer have a\nstage distribution like patients with screen-detected lung cancer.\nThe mode of presentation is not actionable\nat the point of care for an individual patient, though programmatic and systemic efforts to increase\nimplementation of lung cancer screening and multi-disciplinary clinics for patients with incidentally or screen-\ndetected lung nodules may improve outcomes at the population level.\nAJCC Level of Evidence: I\nFunctional Status\nGreater limitations in functional status \u2014 as measured by a variety of methods including but not limited to self-\nreported and clinician-reported \u2014 are associated with lower survival rates among treated patients with lung\ncancer.\nDecrements in functional status influence treatment decisions. Functional status is likely colinear\nwith the severity of some comorbid conditions. Documentation of functional status may support decisions to\ndeviate from evidence-based and guideline-recommended treatments for lung cancer. AJCC Level of Evidence: I\nComorbid Conditions Posing a Competing Risk of Death\nComorbid conditions posing a competing risk of death are associated with lower survival rates and they impact\ntreatment decisions like other factors such as functional status (see above). Importantly, the diagnosis of\ncomorbid conditions does not necessarily influence treatment decisions or survival \u2014 rather the severity of the\ncomorbid condition impacts treatment decisions and long-term outcomes. The severity of comorbid conditions\nmay reasonably manifest as functional status. However, some conditions pose a well-documented competing\nrisk of death. For instance, 5-year overall survival rates for patients with moderate aortic stenosis or long-term\ndialysis for end-stage renal disease are 50% and 40%, respectively.\nIn contrast, 5-year overall survival for a\nperipheral, < 2 cm, stage IA NSCLC treated with surgical resection is 80%.\nConcomitant diagnoses of stage IA\nNSCLC and moderate aortic stenosis or long-term dialysis for end-stage renal disease serves as an example of\nhow a comorbid condition can pose a competing risk for death potentially impacting treatment decisions. AJCC\nLevel of Evidence: I\nQuality of Care\nDeviation from guideline recommended staging occurs commonly in the United States, and such deviations are\nassociated with worse patient outcomes. Patterns of care studies describe underuse and inexplicably variable\nuse of imaging, pretreatment nodal staging with EBUS or mediastinoscopy, and intraoperative lymph node\ndissection.\nInadequate sampling of lymph nodes at the time of EBUS or mediastinoscopy has also been\ndescribed.\nRandomized trials support the use of advanced imaging such as PET for lung cancer staging\nwith a demonstrated positive impact on subsequent care and patient outcomes.\nObservational studies have\ndemonstrated that the following are all associated with worse long-term survival: underuse of lung cancer staging\nmodalities,\nguideline discordant pretreatment nodal staging,\nand no or inadequate intraoperative lymph\nnode dissection.\nThough possibly difficult to act at the level of an individual patient encounter because of\nlimited resources or access to high-quality, specialty care, programmatic and systemic efforts to implement\nguideline recommended staging\nand refer patients to specialists\nmay lead to benefits at the population level.\nAJCC Level of Evidence: I\nRationale for Changes and Future Directions\nRevisions from the 8  Edition to Version 9 of TNM classification were made according to prognostic analyses of\nthe data from the IASLC database that included more than 80,000 evaluable patients with lung cancer. While\nconducting detailed evaluations of TNM factors, our challenge was to balance high specificity in prognostic\ncharacterization with simplicity and user-friendliness. The fundamental concept is to group the tumors with\nsimilar prognostic characteristics together, and to determine the appropriate combination of T, N, and M for the\nstage. Future direction of TNM classification would be to include the non-anatomic factors such as molecular\nbiomarkers and gene mutations. These non-anatomic factors were not used in Version 9 because of the lack of\n70-72\n73, 74\n74, 75\n76-78\n79\n46\n80-83\n84-86\n87-91\n92\n85, 93\n41, 94-96\n15\n97\nth", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841751", "page": 45, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 4684}}
{"chunk_id": "tnm_lung_chunk_104", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n46/60\n\nsolid data, but they might be incorporated in Version 10 to help clinicians stratify tumors based on expected\nprognosis.\nSupplemental Information\nAJCC Levels of Evidence\nLevel I\nThe available evidence includes consistent results from multiple large, well-designed, and well-\nconducted national and international studies in appropriate patient populations, with appropriate\nendpoints and appropriate treatments.\nBoth prospective studies and retrospective population-based registry studies are acceptable;\nstudies should be evaluated on the basis of methodology rather than chronology.\nLevel II\nThe available evidence is obtained from at least 1 large, well-designed, and well-conducted study in\nappropriate patient populations with appropriate endpoints and with external validation.\nLevel III\nThe available evidence is somewhat problematic because of a factor such as the number, size, or\nquality of individual studies; inconsistency of results across individual studies; appropriateness of\npatient population used in 1 or more studies; or the appropriateness of outcomes used in 1 or more\nstudies.\nLevel IV The available evidence is insufficient because appropriate studies have not yet been performed.\nTable adapted from Amin et al.\nGeneral Staging Rules\nThese general rules apply to the application of T, N, and M categories for all anatomic sites and classifications.\nTopic\nRules\nMicroscopic confirmation\n\u2022 Microscopic confirmation is necessary for TNM classification, including clinical\nclassification (with rare exception).\n\u2022 In rare clinical scenarios, patients who do not have any biopsy or cytology of\nthe tumor may be staged. This is recommended in rare clinical situations,\nonly if the cancer diagnosis is NOT in doubt. In the absence of histologic\nconfirmation, survival analysis may be performed separately from staged\ncohorts with histologic confirmation. Separate survival analysis is not required\nif clinical findings support a cancer diagnosis and specific site.\nExample: Lung cancer diagnosed by CT scan only, that is, without a confirmatory\nbiopsy\nTime frame/staging\nwindow for determining\nclinical stage\nInformation gathered about the extent of the cancer is part of clinical\nclassification:\n\u2022 from date of diagnosis before initiation of primary treatment or decision for\nwatchful waiting or supportive care to one of the following time points,\nwhichever is shortest:\n\u25aa 4 months after diagnosis\n52", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841754", "page": 46, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 2586}}
{"chunk_id": "tnm_lung_chunk_105", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n47/60\n\n\u25aa to the date of cancer progression if the cancer progresses before the end of\nthe 4 month window; data on the extent of the cancer is only included\nbefore the date of observed progression\nTime frame/staging\nwindow for determining\npathological stage\nInformation including clinical staging data and information from surgical resection\nand examination of the resected specimens \u2014 if surgery is performed before the\ninitiation of radiation and/or systemic therapy \u2014 from the date of diagnosis:\n\u2022 within 4 months after diagnosis\n\u2022 to the date of cancer progression if the cancer progresses before the end of\nthe 4-month window; data on the extent of the cancer is included only before\nthe date of observed progression\n\u2022 and includes any information obtained about the extent of cancer up through\ncompletion of definitive surgery as part of primary treatment if that surgery\noccurs later than 4 months after diagnosis and the cancer has not clearly\nprogressed during the time window\nNote: Patients who receive radiation and/or systemic therapy (neoadjuvant\ntherapy) before surgical resection are not assigned a pathological category or\nstage, and instead are staged according to post neoadjuvant therapy criteria.\nTime frame/staging\nwindow for staging post\nneoadjuvant therapy or\nposttherapy\nAfter completion of neoadjuvant therapy, patients should be staged as:\n\u2022 yc: posttherapy clinical\nAfter completion of neoadjuvant therapy followed by surgery, patients should be\nstaged as:\n\u2022 yp: posttherapy pathological\nThe time frame should be such that the post neoadjuvant surgery and staging\noccur within a time frame that accommodates disease-specific circumstances, as\noutlined in the specific disease sites and in relevant guidelines.\nNote: Clinical stage should be assigned before the start of neoadjuvant therapy.\nProgression of disease\nIf there is documented progression of cancer before therapy or surgery, only\ninformation obtained before the documented progression is used for clinical and\npathological staging.\nProgression does not include growth during the time needed for the diagnostic\nworkup, but rather a major change in clinical status.\nDetermination of progression is based on managing physician judgment, and may\nresult in a major change in the treatment plan.\nUncertainty among T, N,\nor M categories, and/or\nIf uncertainty exists regarding how to assign a category, subcategory, or stage\ngroup, the lower of the two possible categories, subcategories, or groups is", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841757", "page": 47, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 2643}}
{"chunk_id": "tnm_lung_chunk_106", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n48/60\n\nstage groups: rules for\nclinical decision making\nassigned for\n\u2022 T, N, or M\n\u2022 prognostic stage group/stage group\nStage groups are for patient care and prognosis based on data. Physicians may\nneed to make treatment decisions if staging information is uncertain or unclear.\nNote: Unknown or missing information for T, N, M or stage group is never\nassigned the lower category, subcategory, or group.\nUncertainty rules do not\napply to cancer registry\ndata\nIf information is not available to the cancer registrar for documentation of a\nsubcategory, the main (umbrella) category should be assigned (e.g., T1 for a\nbreast cancer described as <2 cm in place of T1a, T1b, or T1c).\nIf the specific information to assign the stage group is not available to the cancer\nregistrar (including subcategories or missing prognostic factor categories), the\nstage group should not be assigned but should be documented as unknown.\nPrognostic factor category\ninformation is unavailable\nIf a required prognostic factor category is unavailable, the category used to assign\nthe stage group is:\n\u2022 X, or\n\u2022 If the prognostic factor is unavailable, default to assigning the anatomic stage\nusing clinical judgment.\nGrade\nThe recommended histologic grading system for each disease site and/or cancer\ntype, if applicable, is specified in each disease site and should be used by the\npathologist to assign grade.\nThe cancer registrar will document grade for a specific site according to the\ncoding structure in the relevant disease site.\nSynchronous primary\ntumors in a single organ:\n(m) suffix\nIf multiple tumors of the same histology are present in one organ:\n\u2022 the tumor with the highest T category is classified and staged, and\n\u2022 the (m) suffix is used\n\u2022 An example of a preferred designation is: pT3(m) N0 M0.\n\u2022 If the number of synchronous tumors is important, an acceptable alternative\ndesignation is to specify the number of tumors. For example, pT3(4) N0 M0\nindicates four synchronous primary tumors.\nNote: The (m) suffix applies to multiple invasive cancers. It is not applicable for\nmultiple foci of in situ cancer or for a mixed invasive and in situ cancer.\nSynchronous primary\ntumors in paired organs\nCancers occurring at the same time in each of paired organs are staged as\nseparate cancers. Examples include breast, lung, and kidney.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841760", "page": 48, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 2482}}
{"chunk_id": "tnm_lung_chunk_107", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n49/60\n\nException: For tumors of the thyroid, liver, and ovary, multiplicity is a T-category\ncriterion, thus multiple synchronous tumors are not staged independently.\nMetachronous primary\ntumors\nSecond or subsequent primary cancers occurring in the same organ or in different\norgans outside the staging window are staged independently and are known as\nmetachronous primary tumors.\nSuch cancers are not staged using the y prefix.\nUnknown primary or no\nevidence of primary tumor\nIf there is no evidence of a primary tumor, or the site of the primary tumor is\nunknown, staging may be based on the clinical suspicion of the organ site of the\nprimary tumor, with the tumor categorized as T0. The rules for staging cancers\ncategorized as T0 are specified in the relevant disease sites.\nExample: An axillary lymph node with an adenocarcinoma in a woman, suspected\nclinically to be from the breast, may be categorized as T0 N1 (or N2 or N3) M0\nand assigned Stage II (or Stage III).\nExamples of exception: The T0 category is not used for head and neck\nsquamous cancer sites, as such patients with an involved lymph node are staged\nas unknown primary cancers using the \"Cervical Nodes and Unknown Primary\nTumors of the Head and Neck\" system (T0 remains a valid category for human\npapillomavirus [HPV]- and Epstein-Barr virus [EBV]-associated oropharyngeal\nand nasopharyngeal cancers).\nDate of diagnosis\nIt is important to document the date of diagnosis, because this information is used\nfor survival calculations and time periods for staging.\nThe date of diagnosis is the date a physician determines the patient has cancer. It\nmay be the date of a diagnostic biopsy or other microscopic confirmation or of\nclear evidence on imaging. This rule varies by disease site and shares similarities\nwith the earlier discussion on microscopic confirmation.\nStage Classifications\nStage classifications are determined according to the point in time of the patient's care in relation to diagnosis\nand treatment. The five stage classifications are clinical, pathological, posttherapy/post neoadjuvant therapy,\nrecurrence/retreatment, and autopsy.\nClassification\nDesignation\nDetails\nClinical\ncTNM or TNM Criteria: used for all patients with cancer identified before treatment\nIt is composed of diagnostic workup information, until first treatment,\nincluding:\n\u2022 clinical history and symptoms\n\u2022 physical examination\n\u2022 imaging", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841763", "page": 49, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 2559}}
{"chunk_id": "tnm_lung_chunk_108", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n50/60\n\n\u2022 endoscopy\n\u2022 biopsy of the primary site\n\u2022 biopsy or excision of a single regional node or sentinel nodes, or\nsampling of regional nodes, with clinical T\n\u2022 biopsy of distant metastatic site\n\u2022 surgical exploration without resection\n\u2022 other relevant examinations\nNote: Exceptions exist by site, such as complete excision of primary\ntumor for melanoma.\nPathological\npTNM\nCriteria: used for patients if surgery is the first definitive therapy\nIt is composed of information from:\n\u2022 diagnostic workup from clinical staging combined with\n\u2022 operative findings, and\n\u2022 pathology review of resected surgical specimens\nPosttherapy or post\nneoadjuvant therapy\nycTNM and\nypTNM\nFor purposes of posttherapy or post neoadjuvant therapy, neoadjuvant\ntherapy is defined as systemic and/or radiation therapy given before\nsurgery; primary radiation and/or systemic therapy is treatment given as\ndefinitive therapy without surgery.\nyc\nThe yc classification is used for staging after primary systemic and/or\nradiation therapy, or after neoadjuvant therapy and before planned\nsurgery\nCriteria: First therapy is systemic and/or radiation therapy\nyp\nThe yp classification is used for staging after neoadjuvant therapy and\nplanned post neoadjuvant therapy surgery\nCriteria: First therapy is systemic and/or radiation therapy and is\nfollowed by surgery.\nRecurrence or\nretreatment\nrTNM\nThis classification is used for assigning stage at time of recurrence or\nprogression until treatment is initiated.\nCriteria: Disease recurrence after disease-free interval or upon disease\nprogression if further treatment is planned for a cancer that:", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841766", "page": 50, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 1776}}
{"chunk_id": "tnm_lung_chunk_109", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n51/60\n\n\u2022 recurs after a disease-free interval or\n\u2022 progresses (without a disease-free interval)\nrc\nClinical recurrence staging is assigned as rc\nrp\nPathological staging information is assigned as rp for the rTNM staging\nclassification\nThis classification is recorded in addition to and does not replace the\noriginal previously assigned clinical (c), pathological (p), and/or\nposttherapy (yc, yp) stage classifications, and these previously\ndocumented classifications are not changed\nAutopsy\naTNM\nThis classification is used for cancers not previously recognized that are\nfound as an incidental finding at autopsy, and not suspected before\ndeath (i.e., this classification does not apply if an autopsy is performed\nin a patient with a previously diagnosed cancer).\nCriteria: No cancer suspected prior to death\nBoth clinical and pathological staging information is used to assign\naTNM\nAuthors\nAuthors: Hisao Asamura, Farhood Farjah, Ritu Gill, Raymond U. Osarogiagbon, Ram\u00f3n Rami-Porta, William D.\nTravis, Chu-Fu Yang, and Masaya Yotsukura, for the American Joint Committee on Cancer Expert Panel on\nCancers of the Lung.\nAcknowledgements and disclaimers: With guidance from Elliot A. Asare, Ronald Weigel, Donna M. Gress,\nAleisha J. Williams, Elaine Alexander, AJCC Staff, AJCC Expert Panel for Lung, AJCC Editorial Committee, and\nAJCC Executive Committee\nAuthor contributions: HA, FF, RG, RUO, RRP, WDT, CFY, MY wrote the manuscript, performed critical revision of\nthe manuscript for important intellectual content, reviewed and approved the manuscript.\nIllustrations: Reprinted courtesy of the International Association for the Study of Lung Cancer. Copyright \u00a92024,\nAletta Ann Frazier.\nRitu Gill created the radiological illustrations for adenocarcinomas and multiple tumors.\nWilliam D. Travis created illustrations comparing radiology and pathology.\nKellie M. Holoski revised the illustrations.\nThis Cancer Staging Protocol was prepared and published through the generous support of the American Cancer\nSociety.\nReferences", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841769", "page": 51, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 2186}}
{"chunk_id": "tnm_lung_chunk_110", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n52/60\n\n1.\nAmin MB. The AJCC Cancer Staging Manual. Springer; 2017.\n2.\nWHO Classification of Tumours Editorial Board., World Health Organization, International Agency for\nResearch on Cancer. WHO classification of tumours : thoracic malignancies. Lyon: International Agency\nfor Research on Cancer; 2021.\n3.\nWorld Health Organization. International Classification of Diseases for Oncology. ICD-O-3.2 Online.\n4.\nSung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence\nand Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71:209-249.\n5.\nAsamura H, Nishimura KK, Giroux DJ, et al. IASLC Lung Cancer Staging Project: The New Database to", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841771", "page": 52, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 860}}
{"chunk_id": "tnm_lung_chunk_111", "text": "Inform Revisions in the Ninth Edition of the TNM Classification of Lung Cancer. J Thorac Oncol\n\n2023;18:564-575.\n6.\nVan Schil PE, Asamura H, Nishimura KK, et al. The International Association for the Study of Lung\nCancer Lung Cancer Staging Project: Proposals for the Revisions of the T-Descriptors in the Forthcoming", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841774", "page": 53, "cancer_type": "Lung", "category": "M-staging", "section": "Inform Revisions in the Ninth Edition of the TNM Classification of Lung Cancer. J Thorac Oncol", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 317}}
{"chunk_id": "tnm_lung_chunk_112", "text": "Ninth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2024;19:749-765.\n\n7.\nHuang J, Osarogiagbon RU, Giroux DJ, et al. The International Association for the Study of Lung Cancer\nStaging Project for Lung Cancer: Proposals for the Revision of the N Descriptors in the Forthcoming Ninth", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841777", "page": 53, "cancer_type": "Lung", "category": "M-staging", "section": "Ninth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2024;19:749-765.", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 301}}
{"chunk_id": "tnm_lung_chunk_113", "text": "Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2024;19:766-785.\n\n8.\nFong KM, Rosenthal A, Giroux DJ, et al. The International Association for the Study of Lung Cancer\nStaging Project for Lung Cancer: Proposals for the Revision of the M Descriptors in the Forthcoming", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841780", "page": 53, "cancer_type": "Lung", "category": "M-staging", "section": "Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2024;19:766-785.", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 285}}
{"chunk_id": "tnm_lung_chunk_114", "text": "Ninth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2024;19:786-802.\n\n9.\nRami-Porta R, Nishimura KK, Giroux DJ, et al. The International Association for the Study of Lung Cancer\nLung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming\n(Ninth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2024;19:1007-1027.\n10. Wittekind C. TNM supplement: a commentary on uniform use. John Wiley & Sons; 2012.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841783", "page": 53, "cancer_type": "Lung", "category": "M-staging", "section": "Ninth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2024;19:786-802.", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 472}}
{"chunk_id": "tnm_lung_chunk_115", "text": "11. Moreira AL, Ocampo PSS, Xia Y, et al. A Grading System for Invasive Pulmonary Adenocarcinoma: A\n\nProposal From the International Association for the Study of Lung Cancer Pathology Committee. J Thorac\nOncol 2020;15:1599-1610.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841786", "page": 53, "cancer_type": "Lung", "category": "Unknown", "section": "11. Moreira AL, Ocampo PSS, Xia Y, et al. A Grading System for Invasive Pulmonary Adenocarcinoma: A", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 228}}
{"chunk_id": "tnm_lung_chunk_116", "text": "12. Tan KS, Reiner A, Emoto K, et al. Novel Insights Into the International Association for the Study of Lung\n\nCancer Grading System for Lung Adenocarcinoma. Mod Pathol 2024;37:100520.\n13. Asamura H. IASLC Staging Manual in Thoracic Oncology, 3rd Edition Editorial Rx Press; 2024.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841789", "page": 53, "cancer_type": "Lung", "category": "Unknown", "section": "12. Tan KS, Reiner A, Emoto K, et al. Novel Insights Into the International Association for the Study of Lung", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 280}}
{"chunk_id": "tnm_lung_chunk_117", "text": "14. Postmus PE, Rocmans P, Asamura H, et al. Consensus report IASLC workshop Bruges, September\n\n2002: pretreatment minimal staging for non-small cell lung cancer. Lung Cancer 2003;42 Suppl 1:S3-6.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841793", "page": 53, "cancer_type": "Lung", "category": "Unknown", "section": "14. Postmus PE, Rocmans P, Asamura H, et al. Consensus report IASLC workshop Bruges, September", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 196}}
{"chunk_id": "tnm_lung_chunk_118", "text": "15. Silvestri GA, Gonzalez AV, Jantz MA, et al. Methods for staging non-small cell lung cancer: Diagnosis and\n\nmanagement of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical\npractice guidelines. Chest 2013;143:e211S-e250S.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841796", "page": 53, "cancer_type": "Lung", "category": "Unknown", "section": "15. Silvestri GA, Gonzalez AV, Jantz MA, et al. Methods for staging non-small cell lung cancer: Diagnosis and", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 255}}
{"chunk_id": "tnm_lung_chunk_119", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n53/60", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841798", "page": 53, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 167}}
{"chunk_id": "tnm_lung_chunk_120", "text": "16. Paesmans M, Garcia C, Wong CY, et al. Primary tumour standardised uptake value is prognostic in\n\nnonsmall cell lung cancer: a multivariate pooled analysis of individual data. Eur Respir J 2015;46:1751-\n1761.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841801", "page": 54, "cancer_type": "Lung", "category": "Unknown", "section": "16. Paesmans M, Garcia C, Wong CY, et al. Primary tumour standardised uptake value is prognostic in", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 211}}
{"chunk_id": "tnm_lung_chunk_121", "text": "17. Davis PC, Hudgins PA, Peterman SB, et al. Diagnosis of cerebral metastases: double-dose delayed CT\n\nvs contrast-enhanced MR imaging. AJNR Am J Neuroradiol 1991;12:293-300.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841804", "page": 54, "cancer_type": "Lung", "category": "Unknown", "section": "17. Davis PC, Hudgins PA, Peterman SB, et al. Diagnosis of cerebral metastases: double-dose delayed CT", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 175}}
{"chunk_id": "tnm_lung_chunk_122", "text": "19. Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. John Wiley & Sons;\n\n2011.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841807", "page": 54, "cancer_type": "Lung", "category": "M-staging", "section": "19. Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. John Wiley & Sons;", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 111}}
{"chunk_id": "tnm_lung_chunk_123", "text": "20. Rivera MP, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer: Diagnosis and management\n\nof lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.\nChest 2013;143:e142S-e165S.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841810", "page": 54, "cancer_type": "Lung", "category": "Unknown", "section": "20. Rivera MP, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer: Diagnosis and management", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 238}}
{"chunk_id": "tnm_lung_chunk_124", "text": "21. De Leyn P, Dooms C, Kuzdzal J, et al. Revised ESTS guidelines for preoperative mediastinal lymph node\n\nstaging for non-small-cell lung cancer. Eur J Cardiothorac Surg 2014;45:787-798.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841813", "page": 54, "cancer_type": "Lung", "category": "Unknown", "section": "21. De Leyn P, Dooms C, Kuzdzal J, et al. Revised ESTS guidelines for preoperative mediastinal lymph node", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 187}}
{"chunk_id": "tnm_lung_chunk_125", "text": "22. Dooms C, Tournoy KG, Schuurbiers O, et al. Endosonography for mediastinal nodal staging of clinical N1\n\nnon-small cell lung cancer: a prospective multicenter study. Chest 2015;147:209-215.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841817", "page": 54, "cancer_type": "Lung", "category": "Unknown", "section": "22. Dooms C, Tournoy KG, Schuurbiers O, et al. Endosonography for mediastinal nodal staging of clinical N1", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 192}}
{"chunk_id": "tnm_lung_chunk_126", "text": "23. Bousema JE, Dijkgraaf MGW, van der Heijden E, et al. Endosonography With or Without Confirmatory\n\nMediastinoscopy for Resectable Lung Cancer: A Randomized Clinical Trial. J Clin Oncol 2023;41:3805-\n3815.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841820", "page": 54, "cancer_type": "Lung", "category": "Unknown", "section": "23. Bousema JE, Dijkgraaf MGW, van der Heijden E, et al. Endosonography With or Without Confirmatory", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 207}}
{"chunk_id": "tnm_lung_chunk_127", "text": "25. Detterbeck FC, Franklin WA, Nicholson AG, et al. The IASLC Lung Cancer Staging Project: Background\n\nData and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841823", "page": 54, "cancer_type": "Lung", "category": "Unknown", "section": "25. Detterbeck FC, Franklin WA, Nicholson AG, et al. The IASLC Lung Cancer Staging Project: Background", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 199}}
{"chunk_id": "tnm_lung_chunk_128", "text": "Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung\n\nCancer. J Thorac Oncol 2016;11:651-665.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841826", "page": 54, "cancer_type": "Lung", "category": "M-staging", "section": "Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 139}}
{"chunk_id": "tnm_lung_chunk_129", "text": "26. Detterbeck FC, Marom EM, Arenberg DA, et al. The IASLC Lung Cancer Staging Project: Background\n\nData and Proposals for the Application of TNM Staging Rules to Lung Cancer Presenting as Multiple\nNodules with Ground Glass or Lepidic Features or a Pneumonic Type of Involvement in the Forthcoming\nEighth Edition of the TNM Classification. J Thorac Oncol 2016;11:666-680.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841845", "page": 54, "cancer_type": "Lung", "category": "Unknown", "section": "26. Detterbeck FC, Marom EM, Arenberg DA, et al. The IASLC Lung Cancer Staging Project: Background", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 371}}
{"chunk_id": "tnm_lung_chunk_130", "text": "Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of\n\nInvolvement in the Forthcoming Eighth Edition of the TNM Classification. J Thorac Oncol 2016;11:639-\n650.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841848", "page": 54, "cancer_type": "Lung", "category": "Unknown", "section": "Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 201}}
{"chunk_id": "tnm_lung_chunk_131", "text": "28. Detterbeck FC, Postmus PE, Tanoue LT. The stage classification of lung cancer: Diagnosis and\n\nmanagement of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical\npractice guidelines. Chest 2013;143:e191S-e210S.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841851", "page": 54, "cancer_type": "Lung", "category": "Unknown", "section": "28. Detterbeck FC, Postmus PE, Tanoue LT. The stage classification of lung cancer: Diagnosis and", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 242}}
{"chunk_id": "tnm_lung_chunk_132", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n54/60", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841854", "page": 54, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 167}}
{"chunk_id": "tnm_lung_chunk_133", "text": "29. Travis WD, Asamura H, Bankier AA, et al. The IASLC Lung Cancer Staging Project: Proposals for Coding\n\nT Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841857", "page": 55, "cancer_type": "Lung", "category": "Unknown", "section": "29. Travis WD, Asamura H, Bankier AA, et al. The IASLC Lung Cancer Staging Project: Proposals for Coding", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 196}}
{"chunk_id": "tnm_lung_chunk_134", "text": "Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. J Thorac Oncol 2016;11:1204-\n\n1223.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841860", "page": 55, "cancer_type": "Lung", "category": "M-staging", "section": "Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. J Thorac Oncol 2016;11:1204-", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 104}}
{"chunk_id": "tnm_lung_chunk_135", "text": "30. Travis WD, Brambilla E, Rami-Porta R, et al. Visceral pleural invasion: pathologic criteria and use of\n\nelastic stains: proposal for the 7th edition of the TNM classification for lung cancer. J Thorac Oncol\n2008;3:1384-1390.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841863", "page": 55, "cancer_type": "Lung", "category": "Unknown", "section": "30. Travis WD, Brambilla E, Rami-Porta R, et al. Visceral pleural invasion: pathologic criteria and use of", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 228}}
{"chunk_id": "tnm_lung_chunk_136", "text": "31. International Agency for Research on Cancer, Travis WD, Brambilla E, et al. WHO Classification of\n\nTumours of the Lung, Pleura, Thymus and Heart. Lyon: International Agency for Research on Cancer;\n2015.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841866", "page": 55, "cancer_type": "Lung", "category": "Unknown", "section": "31. International Agency for Research on Cancer, Travis WD, Brambilla E, et al. WHO Classification of", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 206}}
{"chunk_id": "tnm_lung_chunk_137", "text": "32. Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization Classification of Lung\n\nTumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac\nOncol 2015;10:1243-1260.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841869", "page": 55, "cancer_type": "Lung", "category": "N-staging", "section": "32. Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization Classification of Lung", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 232}}
{"chunk_id": "tnm_lung_chunk_138", "text": "33. Tsutani Y, Miyata Y, Nakayama H, et al. Prognostic significance of using solid versus whole tumor size on\n\nhigh-resolution computed tomography for predicting pathologic malignant grade of tumors in clinical stage\nIA lung adenocarcinoma: a multicenter study. J Thorac Cardiovasc Surg 2012;143:607-612.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841872", "page": 55, "cancer_type": "Lung", "category": "Unknown", "section": "33. Tsutani Y, Miyata Y, Nakayama H, et al. Prognostic significance of using solid versus whole tumor size on", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 304}}
{"chunk_id": "tnm_lung_chunk_139", "text": "34. Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ERS classification of lung\n\nadenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis\nof 514 stage I cases. Mod Pathol 2011;24:653-664.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841875", "page": 55, "cancer_type": "Lung", "category": "Unknown", "section": "34. Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ERS classification of lung", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 253}}
{"chunk_id": "tnm_lung_chunk_140", "text": "35. Maeyashiki T, Suzuki K, Hattori A, et al. The size of consolidation on thin-section computed tomography is\n\na better predictor of survival than the maximum tumour dimension in resectable lung cancer. Eur J\nCardiothorac Surg 2013;43:915-918.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841878", "page": 55, "cancer_type": "Lung", "category": "Unknown", "section": "35. Maeyashiki T, Suzuki K, Hattori A, et al. The size of consolidation on thin-section computed tomography is", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 244}}
{"chunk_id": "tnm_lung_chunk_141", "text": "36. Travis WD, Dacic S, Wistuba I, et al. IASLC Multidisciplinary Recommendations for Pathologic\n\nAssessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. J Thorac Oncol\n2020;15:709-740.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841881", "page": 55, "cancer_type": "Lung", "category": "Unknown", "section": "36. Travis WD, Dacic S, Wistuba I, et al. IASLC Multidisciplinary Recommendations for Pathologic", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 202}}
{"chunk_id": "tnm_lung_chunk_142", "text": "37. Rusch VW, Asamura H, Watanabe H, et al. The IASLC lung cancer staging project: a proposal for a new\n\ninternational lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer.\nJ Thorac Oncol 2009;4:568-577.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841884", "page": 55, "cancer_type": "Lung", "category": "Unknown", "section": "37. Rusch VW, Asamura H, Watanabe H, et al. The IASLC lung cancer staging project: a proposal for a new", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 242}}
{"chunk_id": "tnm_lung_chunk_143", "text": "38. Goldstraw P. Report on the international workshop on intrathoracic staging. London, October 1996. Lung\n\ncancer 1997;18:107-111.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841887", "page": 55, "cancer_type": "Lung", "category": "Unknown", "section": "38. Goldstraw P. Report on the international workshop on intrathoracic staging. London, October 1996. Lung", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 131}}
{"chunk_id": "tnm_lung_chunk_144", "text": "39. Rami-Porta R, Wittekind C, Goldstraw P, et al. Complete resection in lung cancer surgery: proposed\n\ndefinition. Lung Cancer 2005;49:25-33.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841891", "page": 55, "cancer_type": "Lung", "category": "Unknown", "section": "39. Rami-Porta R, Wittekind C, Goldstraw P, et al. Complete resection in lung cancer surgery: proposed", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 142}}
{"chunk_id": "tnm_lung_chunk_145", "text": "Cancer Lung Cancer Staging Project: Proposals for Revision of the Classification of Residual Tumor After\n\nResection for the Forthcoming (Ninth) Edition of the TNM Classification of Lung Cancer. J Thorac Oncol\n2024;19:1052-1072.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841894", "page": 55, "cancer_type": "Lung", "category": "Unknown", "section": "Cancer Lung Cancer Staging Project: Proposals for Revision of the Classification of Residual Tumor After", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 227}}
{"chunk_id": "tnm_lung_chunk_146", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n55/60", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841897", "page": 55, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 167}}
{"chunk_id": "tnm_lung_chunk_147", "text": "41. Osarogiagbon RU, Allen JW, Farooq A, et al. Outcome of surgical resection for pathologic N0 and Nx\n\nnon-small cell lung cancer. J Thorac Oncol 2010;5:191-196.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841900", "page": 56, "cancer_type": "Lung", "category": "Unknown", "section": "41. Osarogiagbon RU, Allen JW, Farooq A, et al. Outcome of surgical resection for pathologic N0 and Nx", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 162}}
{"chunk_id": "tnm_lung_chunk_148", "text": "42. Darling GE, Allen MS, Decker PA, et al. Randomized trial of mediastinal lymph node sampling versus\n\ncomplete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-\nsmall cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. J Thorac\nCardiovasc Surg 2011;141:662-670.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841903", "page": 56, "cancer_type": "Lung", "category": "Unknown", "section": "42. Darling GE, Allen MS, Decker PA, et al. Randomized trial of mediastinal lymph node sampling versus", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 343}}
{"chunk_id": "tnm_lung_chunk_149", "text": "43. Osarogiagbon RU, Van Schil P, Giroux DJ, et al. The International Association for the Study of Lung\n\nCancer Lung Cancer Staging Project: Overview of Challenges and Opportunities in Revising the Nodal", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841906", "page": 56, "cancer_type": "Lung", "category": "Unknown", "section": "43. Osarogiagbon RU, Van Schil P, Giroux DJ, et al. The International Association for the Study of Lung", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 203}}
{"chunk_id": "tnm_lung_chunk_150", "text": "44. Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for\n\nRevision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841909", "page": 56, "cancer_type": "Lung", "category": "Unknown", "section": "44. Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 201}}
{"chunk_id": "tnm_lung_chunk_151", "text": "45. Yankelevitz DF, Yip R, Smith JP, et al. CT Screening for Lung Cancer: Nonsolid Nodules in Baseline and\n\nAnnual Repeat Rounds. Radiology 2015;277:555-564.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841913", "page": 56, "cancer_type": "Lung", "category": "Unknown", "section": "45. Yankelevitz DF, Yip R, Smith JP, et al. CT Screening for Lung Cancer: Nonsolid Nodules in Baseline and", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 157}}
{"chunk_id": "tnm_lung_chunk_152", "text": "46. Altorki N, Wang X, Kozono D, et al. Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell\n\nLung Cancer. N Engl J Med 2023;388:489-498.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841916", "page": 56, "cancer_type": "Lung", "category": "Unknown", "section": "46. Altorki N, Wang X, Kozono D, et al. Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 151}}
{"chunk_id": "tnm_lung_chunk_153", "text": "47. Tapias LF, Shen R, Cassivi SD, et al. Impact of FDG PET Standardized Uptake Value in Resected Clinical\n\nStage IA Non-Small Cell Lung Cancer. Ann Thorac Surg 2024;117:1017-1023.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841919", "page": 56, "cancer_type": "Lung", "category": "Unknown", "section": "47. Tapias LF, Shen R, Cassivi SD, et al. Impact of FDG PET Standardized Uptake Value in Resected Clinical", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 180}}
{"chunk_id": "tnm_lung_chunk_154", "text": "48. Travis WD, Eisele M, Nishimura KK, et al. The International Association for the Study of Lung Cancer\n\n(IASLC) Staging Project for Lung Cancer: Recommendation to Introduce Spread Through Air Spaces as a", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841922", "page": 56, "cancer_type": "Lung", "category": "Unknown", "section": "48. Travis WD, Eisele M, Nishimura KK, et al. The International Association for the Study of Lung Cancer", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 205}}
{"chunk_id": "tnm_lung_chunk_155", "text": "Histologic Descriptor in the Ninth Edition of the TNM Classification of Lung Cancer. Analysis of 4061\n\nPathologic Stage I NSCLC. J Thorac Oncol 2024;19:1028-1051.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841925", "page": 56, "cancer_type": "Lung", "category": "M-staging", "section": "Histologic Descriptor in the Ninth Edition of the TNM Classification of Lung Cancer. Analysis of 4061", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 162}}
{"chunk_id": "tnm_lung_chunk_156", "text": "49. Li Y, Adusumilli PS, Chou TY, et al. Pro: \"Is Spread Through Air Spaces an In Vivo Phenomenon or an\n\nInducible Artifact?\". J Thorac Oncol 2024;19:677-697.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841928", "page": 56, "cancer_type": "Lung", "category": "Unknown", "section": "49. Li Y, Adusumilli PS, Chou TY, et al. Pro: \"Is Spread Through Air Spaces an In Vivo Phenomenon or an", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 158}}
{"chunk_id": "tnm_lung_chunk_157", "text": "50. Aly RG, Rekhtman N, Li X, et al. Spread Through Air Spaces (STAS) Is Prognostic in Atypical Carcinoid,\n\nLarge Cell Neuroendocrine Carcinoma, and Small Cell Carcinoma of the Lung. J Thorac Oncol\n2019;14:1583-1593.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841931", "page": 56, "cancer_type": "Lung", "category": "Unknown", "section": "50. Aly RG, Rekhtman N, Li X, et al. Spread Through Air Spaces (STAS) Is Prognostic in Atypical Carcinoid,", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 216}}
{"chunk_id": "tnm_lung_chunk_158", "text": "51. Kadota K, Nitadori JI, Sima CS, et al. Tumor Spread through Air Spaces is an Important Pattern of\n\nInvasion and Impacts the Frequency and Location of Recurrences after Limited Resection for Small\nStage I Lung Adenocarcinomas. J Thorac Oncol 2015;10:806-814.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841934", "page": 56, "cancer_type": "Lung", "category": "Unknown", "section": "51. Kadota K, Nitadori JI, Sima CS, et al. Tumor Spread through Air Spaces is an Important Pattern of", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 261}}
{"chunk_id": "tnm_lung_chunk_159", "text": "52. Villalba JA, Shih AR, Sayo TMS, et al. Accuracy and Reproducibility of Intraoperative Assessment on\n\nTumor Spread Through Air Spaces in Stage 1 Lung Adenocarcinomas. J Thorac Oncol 2021;16:619-629.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841938", "page": 56, "cancer_type": "Lung", "category": "Unknown", "section": "52. Villalba JA, Shih AR, Sayo TMS, et al. Accuracy and Reproducibility of Intraoperative Assessment on", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 201}}
{"chunk_id": "tnm_lung_chunk_160", "text": "53. Smeltzer MP, Lin CC, Kong FS, et al. Survival impact of postoperative therapy modalities according to\n\nmargin status in non-small cell lung cancer patients in the United States. J Thorac Cardiovasc Surg\n2017;154:661-672 e610.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841941", "page": 56, "cancer_type": "Lung", "category": "Unknown", "section": "53. Smeltzer MP, Lin CC, Kong FS, et al. Survival impact of postoperative therapy modalities according to", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 229}}
{"chunk_id": "tnm_lung_chunk_161", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n56/60", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841943", "page": 56, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 167}}
{"chunk_id": "tnm_lung_chunk_162", "text": "54. Hancock JG, Rosen JE, Antonicelli A, et al. Impact of adjuvant treatment for microscopic residual disease\n\nafter non-small cell lung cancer surgery. Ann Thorac Surg 2015;99:406-413.\n55. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.\nN Engl J Med 2009;361:947-957.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841946", "page": 57, "cancer_type": "Lung", "category": "Unknown", "section": "54. Hancock JG, Rosen JE, Antonicelli A, et al. Impact of adjuvant treatment for microscopic residual disease", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 323}}
{"chunk_id": "tnm_lung_chunk_163", "text": "56. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for\n\nEuropean patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a\nmulticentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-246.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841949", "page": 57, "cancer_type": "Lung", "category": "Unknown", "section": "56. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 287}}
{"chunk_id": "tnm_lung_chunk_164", "text": "57. Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall Survival with Osimertinib in Untreated,\n\nEGFR-Mutated Advanced NSCLC. N Engl J Med 2020;382:41-50.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841952", "page": 57, "cancer_type": "Lung", "category": "Unknown", "section": "57. Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall Survival with Osimertinib in Untreated,", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 162}}
{"chunk_id": "tnm_lung_chunk_165", "text": "58. Skoulidis F, Li BT, Dy GK, et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N Engl J Med\n\n2021;384:2371-2381.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841956", "page": 57, "cancer_type": "Lung", "category": "Unknown", "section": "58. Skoulidis F, Li BT, Dy GK, et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N Engl J Med", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 125}}
{"chunk_id": "tnm_lung_chunk_166", "text": "59. Janne PA, Riely GJ, Gadgeel SM, et al. Adagrasib in Non-Small-Cell Lung Cancer Harboring a\n\nKRAS(G12C) Mutation. N Engl J Med 2022;387:120-131.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841959", "page": 57, "cancer_type": "Lung", "category": "Unknown", "section": "59. Janne PA, Riely GJ, Gadgeel SM, et al. Adagrasib in Non-Small-Cell Lung Cancer Harboring a", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 147}}
{"chunk_id": "tnm_lung_chunk_167", "text": "60. Wolf J, Seto T, Han JY, et al. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung\n\nCancer. N Engl J Med 2020;383:944-957.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841962", "page": 57, "cancer_type": "Lung", "category": "Unknown", "section": "60. Wolf J, Seto T, Han JY, et al. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 145}}
{"chunk_id": "tnm_lung_chunk_168", "text": "61. Paik PK, Felip E, Veillon R, et al. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping\n\nMutations. N Engl J Med 2020;383:931-943.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841965", "page": 57, "cancer_type": "Lung", "category": "Unknown", "section": "61. Paik PK, Felip E, Veillon R, et al. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 148}}
{"chunk_id": "tnm_lung_chunk_169", "text": "62. Li BT, Smit EF, Goto Y, et al. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N\n\nEngl J Med 2022;386:241-251.\n63. Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer.\nN Engl J Med 2014;371:2167-2177.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841968", "page": 57, "cancer_type": "Lung", "category": "Unknown", "section": "62. Li BT, Smit EF, Goto Y, et al. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 274}}
{"chunk_id": "tnm_lung_chunk_170", "text": "64. Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med\n\n2014;371:1963-1971.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841971", "page": 57, "cancer_type": "Lung", "category": "Unknown", "section": "64. Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 127}}
{"chunk_id": "tnm_lung_chunk_171", "text": "65. Zhou C, Solomon B, Loong HH, et al. First-Line Selpercatinib or Chemotherapy and Pembrolizumab in\n\nRET Fusion-Positive NSCLC. N Engl J Med 2023;389:1839-1850.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841974", "page": 57, "cancer_type": "Lung", "category": "Unknown", "section": "65. Zhou C, Solomon B, Loong HH, et al. First-Line Selpercatinib or Chemotherapy and Pembrolizumab in", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 162}}
{"chunk_id": "tnm_lung_chunk_172", "text": "66. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-\n\nPositive Non-Small-Cell Lung Cancer. N Engl J Med 2016;375:1823-1833.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841977", "page": 57, "cancer_type": "Lung", "category": "Unknown", "section": "66. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 166}}
{"chunk_id": "tnm_lung_chunk_173", "text": "67. Reck M, Rabe KF. Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer. N Engl\n\nJ Med 2017;377:849-861.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841981", "page": 57, "cancer_type": "Lung", "category": "Unknown", "section": "67. Reck M, Rabe KF. Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer. N Engl", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 127}}
{"chunk_id": "tnm_lung_chunk_174", "text": "69. Florez N, Kiel L, Riano I, et al. Lung Cancer in Women: The Past, Present, and Future. Clin Lung Cancer\n\n2024;25:1-8.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841984", "page": 57, "cancer_type": "Lung", "category": "Unknown", "section": "69. Florez N, Kiel L, Riano I, et al. Lung Cancer in Women: The Past, Present, and Future. Clin Lung Cancer", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 121}}
{"chunk_id": "tnm_lung_chunk_175", "text": "70. National Lung Screening Trial Research T, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality\n\nwith low-dose computed tomographic screening. N Engl J Med 2011;365:395-409.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841987", "page": 57, "cancer_type": "Lung", "category": "Unknown", "section": "70. National Lung Screening Trial Research T, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 181}}
{"chunk_id": "tnm_lung_chunk_176", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n57/60", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841989", "page": 57, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 167}}
{"chunk_id": "tnm_lung_chunk_177", "text": "71. Das D, Weiss D, Mostashari F, et al. Enhanced drop-in syndromic surveillance in New York City following\n\nSeptember 11, 2001. J Urban Health 2003;80:i76-88.\n72. de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced Lung-Cancer Mortality with Volume CT\nScreening in a Randomized Trial. N Engl J Med 2020;382:503-513.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841992", "page": 58, "cancer_type": "Lung", "category": "Unknown", "section": "71. Das D, Weiss D, Mostashari F, et al. Enhanced drop-in syndromic surveillance in New York City following", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 323}}
{"chunk_id": "tnm_lung_chunk_178", "text": "73. Farjah F, Monsell SE, Gould MK, et al. Association of the Intensity of Diagnostic Evaluation With\n\nOutcomes in Incidentally Detected Lung Nodules. JAMA Intern Med 2021;181:480-489.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841995", "page": 58, "cancer_type": "Lung", "category": "Unknown", "section": "73. Farjah F, Monsell SE, Gould MK, et al. Association of the Intensity of Diagnostic Evaluation With", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 184}}
{"chunk_id": "tnm_lung_chunk_179", "text": "74. Osarogiagbon RU, Liao W, Faris NR, et al. Lung Cancer Diagnosed Through Screening, Lung Nodule,\n\nand Neither Program: A Prospective Observational Study of the Detecting Early Lung Cancer (DELUGE)\nin the Mississippi Delta Cohort. J Clin Oncol 2022;40:2094-2105.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.841999", "page": 58, "cancer_type": "Lung", "category": "Unknown", "section": "74. Osarogiagbon RU, Liao W, Faris NR, et al. Lung Cancer Diagnosed Through Screening, Lung Nodule,", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 264}}
{"chunk_id": "tnm_lung_chunk_180", "text": "75. Verdial FC, Madtes DK, Cheng GS, et al. Multidisciplinary Team-Based Management of Incidentally\n\nDetected Lung Nodules. Chest 2020;157:985-993.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.842002", "page": 58, "cancer_type": "Lung", "category": "Unknown", "section": "75. Verdial FC, Madtes DK, Cheng GS, et al. Multidisciplinary Team-Based Management of Incidentally", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 147}}
{"chunk_id": "tnm_lung_chunk_181", "text": "76. Sehgal K, Gill RR, Widick P, et al. Association of Performance Status With Survival in Patients With\n\nAdvanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy. JAMA Netw Open\n2021;4:e2037120.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.842005", "page": 58, "cancer_type": "Lung", "category": "Unknown", "section": "76. Sehgal K, Gill RR, Widick P, et al. Association of Performance Status With Survival in Patients With", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 213}}
{"chunk_id": "tnm_lung_chunk_182", "text": "77. Liu MA, Keeney T, Papaila A, et al. Functional Status and Survival in Older Nursing Home Residents With\n\nAdvanced Non-Small-Cell Lung Cancer: A SEER-Medicare Analysis. JCO Oncol Pract 2022;18:e886-\ne895.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.842008", "page": 58, "cancer_type": "Lung", "category": "Unknown", "section": "77. Liu MA, Keeney T, Papaila A, et al. Functional Status and Survival in Older Nursing Home Residents With", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 207}}
{"chunk_id": "tnm_lung_chunk_183", "text": "78. Onaitis MW, Furnary AP, Kosinski AS, et al. Prediction of Long-Term Survival After Lung Cancer Surgery\n\nfor Elderly Patients in The Society of Thoracic Surgeons General Thoracic Surgery Database. Ann Thorac\nSurg 2018;105:309-316.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.842011", "page": 58, "cancer_type": "Lung", "category": "Unknown", "section": "78. Onaitis MW, Furnary AP, Kosinski AS, et al. Prediction of Long-Term Survival After Lung Cancer Surgery", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 233}}
{"chunk_id": "tnm_lung_chunk_184", "text": "79. Jacquemyn X, Strom JB, Strange G, et al. Moderate Aortic Valve Stenosis Is Associated With Increased\n\nMortality Rate and Lifetime Loss: Systematic Review and Meta-Analysis of Reconstructed Time-to-Event\nData of 409 680 Patients. J Am Heart Assoc 2024;13:e033872.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.842015", "page": 58, "cancer_type": "Lung", "category": "Unknown", "section": "79. Jacquemyn X, Strom JB, Strange G, et al. Moderate Aortic Valve Stenosis Is Associated With Increased", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 266}}
{"chunk_id": "tnm_lung_chunk_185", "text": "80. Little AG, Gay EG, Gaspar LE, et al. National survey of non-small cell lung cancer in the United States:\n\nepidemiology, pathology and patterns of care. Lung Cancer 2007;57:253-260.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.842018", "page": 58, "cancer_type": "Lung", "category": "Unknown", "section": "80. Little AG, Gay EG, Gaspar LE, et al. National survey of non-small cell lung cancer in the United States:", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 184}}
{"chunk_id": "tnm_lung_chunk_186", "text": "81. Krantz SB, Howington JA, Wood DE, et al. Invasive Mediastinal Staging for Lung Cancer by The Society\n\nof Thoracic Surgeons Database Participants. Ann Thorac Surg 2018;106:1055-1062.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.842021", "page": 58, "cancer_type": "Lung", "category": "Unknown", "section": "81. Krantz SB, Howington JA, Wood DE, et al. Invasive Mediastinal Staging for Lung Cancer by The Society", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 185}}
{"chunk_id": "tnm_lung_chunk_187", "text": "82. Flanagan MR, Varghese TK, Jr., Backhus LM, et al. Gaps in Guideline-Concordant Use of Diagnostic\n\nTests Among Lung Cancer Patients. Ann Thorac Surg 2015;100:2006-2012.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.842024", "page": 58, "cancer_type": "Lung", "category": "Unknown", "section": "82. Flanagan MR, Varghese TK, Jr., Backhus LM, et al. Gaps in Guideline-Concordant Use of Diagnostic", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 171}}
{"chunk_id": "tnm_lung_chunk_188", "text": "83. Dinan MA, Curtis LH, Carpenter WR, et al. Variations in use of PET among Medicare beneficiaries with\n\nnon-small cell lung cancer, 1998-2007. Radiology 2013;267:807-817.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.842027", "page": 58, "cancer_type": "Lung", "category": "Unknown", "section": "83. Dinan MA, Curtis LH, Carpenter WR, et al. Variations in use of PET among Medicare beneficiaries with", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 172}}
{"chunk_id": "tnm_lung_chunk_189", "text": "84. Little AG, Rusch VW, Bonner JA, et al. Patterns of surgical care of lung cancer patients. Ann Thorac Surg\n\n2005;80:2051-2056; discussion 2056.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.842031", "page": 58, "cancer_type": "Lung", "category": "Unknown", "section": "84. Little AG, Rusch VW, Bonner JA, et al. Patterns of surgical care of lung cancer patients. Ann Thorac Surg", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 146}}
{"chunk_id": "tnm_lung_chunk_190", "text": "85. Osarogiagbon RU, Lee YS, Faris NR, et al. Invasive mediastinal staging for resected non-small cell lung\n\ncancer in a population-based cohort. J Thorac Cardiovasc Surg 2019;158:1220-1229 e1222.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.842034", "page": 58, "cancer_type": "Lung", "category": "Unknown", "section": "85. Osarogiagbon RU, Lee YS, Faris NR, et al. Invasive mediastinal staging for resected non-small cell lung", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 196}}
{"chunk_id": "tnm_lung_chunk_191", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n58/60\n\nCopyright: Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for\nthis information is the AJCC Cancer Staging System (2025). All rights reserved.\nBibliography", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.842037", "page": 58, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 373}}
{"chunk_id": "tnm_lung_chunk_192", "text": "2025. AJCC Cancer Staging System. American College of Surgeons. STAT!Ref Online Electronic Medical\n\nLibrary. https://online.statref.com/document/KuQS0BgJpUb1fR9gTOA_Oj. 11/8/2025 11:55:37 AM CST (UTC\n-06:00).\nCopyright:", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.842040", "page": 59, "cancer_type": "Lung", "category": "Unknown", "section": "2025. AJCC Cancer Staging System. American College of Surgeons. STAT!Ref Online Electronic Medical", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 219}}
{"chunk_id": "tnm_lung_chunk_193", "text": "86. Thornblade LW, Wood DE, Mulligan MS, et al. Variability in invasive mediastinal staging for lung cancer: A\n\nmulticenter regional study. J Thorac Cardiovasc Surg 2018;155:2658-2671 e2651.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.842043", "page": 59, "cancer_type": "Lung", "category": "Unknown", "section": "86. Thornblade LW, Wood DE, Mulligan MS, et al. Variability in invasive mediastinal staging for lung cancer: A", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 190}}
{"chunk_id": "tnm_lung_chunk_194", "text": "87. Fischer B, Lassen U, Mortensen J, et al. Preoperative staging of lung cancer with combined PET-CT. N\n\nEngl J Med 2009;361:32-39.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.842046", "page": 59, "cancer_type": "Lung", "category": "Unknown", "section": "87. Fischer B, Lassen U, Mortensen J, et al. Preoperative staging of lung cancer with combined PET-CT. N", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 132}}
{"chunk_id": "tnm_lung_chunk_195", "text": "88. Herder GJ, Kramer H, Hoekstra OS, et al. Traditional versus up-front [18F] fluorodeoxyglucose-positron\n\nemission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. J Clin\nOncol 2006;24:1800-1806.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.842049", "page": 59, "cancer_type": "Lung", "category": "Unknown", "section": "88. Herder GJ, Kramer H, Hoekstra OS, et al. Traditional versus up-front [18F] fluorodeoxyglucose-positron", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 236}}
{"chunk_id": "tnm_lung_chunk_196", "text": "89. Maziak DE, Darling GE, Inculet RI, et al. Positron emission tomography in staging early lung cancer: a\n\nrandomized trial. Ann Intern Med 2009;151:221-228, W-248.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.842052", "page": 59, "cancer_type": "Lung", "category": "Unknown", "section": "89. Maziak DE, Darling GE, Inculet RI, et al. Positron emission tomography in staging early lung cancer: a", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 165}}
{"chunk_id": "tnm_lung_chunk_197", "text": "90. Rossner MT, Jackson RJ, Murray K. Modulation of expression of the hepatitis B virus surface antigen\n\ngene by the viral X-gene product. Proc Biol Sci 1990;241:51-58.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.842055", "page": 59, "cancer_type": "Lung", "category": "Unknown", "section": "90. Rossner MT, Jackson RJ, Murray K. Modulation of expression of the hepatitis B virus surface antigen", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 168}}
{"chunk_id": "tnm_lung_chunk_198", "text": "91. Viney RC, Boyer MJ, King MT, et al. Randomized controlled trial of the role of positron emission\n\ntomography in the management of stage I and II non-small-cell lung cancer. J Clin Oncol 2004;22:2357-\n2362.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.842058", "page": 59, "cancer_type": "Lung", "category": "Unknown", "section": "91. Viney RC, Boyer MJ, King MT, et al. Randomized controlled trial of the role of positron emission", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 209}}
{"chunk_id": "tnm_lung_chunk_199", "text": "92. Farjah F, Flum DR, Ramsey SD, et al. Multi-modality mediastinal staging for lung cancer among medicare\n\nbeneficiaries. J Thorac Oncol 2009;4:355-363.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.842061", "page": 59, "cancer_type": "Lung", "category": "Unknown", "section": "92. Farjah F, Flum DR, Ramsey SD, et al. Multi-modality mediastinal staging for lung cancer among medicare", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 153}}
{"chunk_id": "tnm_lung_chunk_200", "text": "93. Ost DE, Niu J, Zhao H, et al. Quality Gaps and Comparative Effectiveness in Lung Cancer Staging and\n\nDiagnosis. Chest 2020;157:1322-1345.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.842064", "page": 59, "cancer_type": "Lung", "category": "Unknown", "section": "93. Ost DE, Niu J, Zhao H, et al. Quality Gaps and Comparative Effectiveness in Lung Cancer Staging and", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 141}}
{"chunk_id": "tnm_lung_chunk_201", "text": "94. Osarogiagbon RU, Decker PA, Ballman K, et al. Survival Implications of Variation in the Thoroughness of\n\nPathologic Lymph Node Examination in American College of Surgeons Oncology Group Z0030 (Alliance).\nAnn Thorac Surg 2016;102:363-369.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.842067", "page": 59, "cancer_type": "Lung", "category": "Unknown", "section": "94. Osarogiagbon RU, Decker PA, Ballman K, et al. Survival Implications of Variation in the Thoroughness of", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 241}}
{"chunk_id": "tnm_lung_chunk_202", "text": "95. Osarogiagbon RU, Yu X. Mediastinal lymph node examination and survival in resected early-stage non-\n\nsmall-cell lung cancer in the surveillance, epidemiology, and end results database. J Thorac Oncol\n2012;7:1798-1806.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.842071", "page": 59, "cancer_type": "Lung", "category": "Unknown", "section": "95. Osarogiagbon RU, Yu X. Mediastinal lymph node examination and survival in resected early-stage non-", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 221}}
{"chunk_id": "tnm_lung_chunk_203", "text": "96. Allen JW, Farooq A, O'Brien TF, et al. Quality of surgical resection for nonsmall cell lung cancer in a US\n\nmetropolitan area. Cancer 2011;117:134-142.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.842074", "page": 59, "cancer_type": "Lung", "category": "Unknown", "section": "96. Allen JW, Farooq A, O'Brien TF, et al. Quality of surgical resection for nonsmall cell lung cancer in a US", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 155}}
{"chunk_id": "tnm_lung_chunk_204", "text": "97. Farjah F, Flum DR, Varghese TK, Jr., et al. Surgeon specialty and long-term survival after pulmonary\n\nresection for lung cancer. Ann Thorac Surg 2009;87:995-1004; discussion 1005-1006.", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.842077", "page": 59, "cancer_type": "Lung", "category": "Unknown", "section": "97. Farjah F, Flum DR, Varghese TK, Jr., et al. Surgeon specialty and long-term survival after pulmonary", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 188}}
{"chunk_id": "tnm_lung_chunk_205", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n59/60\n\nCopyright \u00a9 Teton Data Systems 2025\nProvided by: University of Texas - Austin\nCopyright: Used with permission of the American College of Surgeons, Chicago, Illinois. The original source\nfor this information is the AJCC Cancer Staging System (2025). All rights reserved.\nDatabase Title:\nSTAT!Ref Online Electronic Medical Library\nDate Accessed:", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.842079", "page": 59, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 512}}
{"chunk_id": "tnm_lung_chunk_206", "text": "11/8/2025 11:55:37 AM CST (UTC -06:00)\n\nElectronic Address:\nhttps://online.statref.com/document/KuQS0BgJpUb1fR9gTOA_Oj\nLocation in Title:", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.842082", "page": 60, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/2025 11:55:37 AM CST (UTC -06:00)", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 137}}
{"chunk_id": "tnm_lung_chunk_207", "text": "AJCC CANCER STAGING SYSTEM - VERSION 9 (2025)\n\nThorax\nLung: Protocol for Cancer Staging Documentation\nPublication Year:\n2025\nPublisher:\nAmerican College of Surgeons\nTitle:\nAJCC Cancer Staging System - Version 9 (2025)", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.842085", "page": 60, "cancer_type": "Lung", "category": "Unknown", "section": "AJCC CANCER STAGING SYSTEM - VERSION 9 (2025)", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 217}}
{"chunk_id": "tnm_lung_chunk_208", "text": "11/8/25, 11:55 AM\n\nLung: Protocol for Cancer Staging Documentation - TDS Health\nhttps://online-statref-com.ezproxy.lib.utexas.edu/document/KuQS0BgJpUb1fR9gTOA_Oj\n60/60", "source_type": "tnm_lung_protocol", "metadata": {"source_file": "Lung_ Protocol for Cancer Staging Documentation.pdf", "created_at": "2025-11-11T17:46:16.842088", "page": 60, "cancer_type": "Lung", "category": "Unknown", "section": "11/8/25, 11:55 AM", "subsection": null, "tnm_edition": "9th", "protocol_type": "staging_documentation", "chunk_method": "semantic", "char_count": 167}}
